

Barkema, H. W. et al. (2018) Knowledge gaps that hamper prevention and control of *Mycobacterium avium* subspecies paratuberculosis infection. *Transboundary and Emerging Diseases*, 65(S1), pp. 125-148.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

Barkema, H. W. et al. (2018) Knowledge gaps that hamper prevention and control of *Mycobacterium avium* subspecies paratuberculosis infection. *Transboundary and Emerging Diseases*, 65(S1), pp. 125-148. (doi:[10.1111/tbed.12723](https://doi.org/10.1111/tbed.12723))

This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

<http://eprints.gla.ac.uk/148807/>

Deposited on: 27 September 2017

1 **RUNNING HEAD: BOTTLENECKS IN JOHNE’S DISEASE CONTROL**

2

3 **Knowledge gaps that hamper prevention and control of *Mycobacterium avium***
4 **subspecies *paratuberculosis* infection**

5

6 Herman W. Barkema¹, Karin Orsel¹, Søren S. Nielsen², Ad P. Koets^{3,4}, Victor P. Rutten³,
7 John P. Bannantine⁵, Greg P. Keefe⁶, David F. Kelton⁷, Scott J. Wells⁸, Richard J.
8 Whittington⁹, Colin G. Mackintosh¹⁰, Elizabeth J. Manning¹¹, Maarten F. Weber¹², Cord
9 Heuer¹³, Taya Forde¹⁴, Caroline Ritter¹, Steven Roche⁷, Caroline Corbett¹, Robert Wolf¹⁵,
10 Philip Griebel¹⁶, John P. Kastelic¹, and Jeroen De Buck¹

11

12 ¹ Dept. of Production Animal Health, Faculty of Veterinary Medicine, University of
13 Calgary, Calgary, AB, Canada

14 ² Univ. of Copenhagen, Denmark

15 ³ Utrecht University, The Netherlands

16 ⁴ Wageningen Bioveterinary Research, The Netherlands

17 ⁵ National Animal Disease Center, USDA-ARS, Ames, IA, USA

18 ⁶ University of Prince Edward Island, Canada

19 ⁷ University of Guelph, Canada

20 ⁸ University of Minnesota, USA

21 ⁹ University of Sydney, Australia

22 ¹⁰ AgResearch, New Zealand

23 ¹¹ University of Wisconsin, USA

1 ¹² GD Animal Health, The Netherlands

2 ¹³ Massey University, New Zealand

3 ¹⁴ University of Glasgow, United Kingdom

4 ¹⁵ Amt der Steiermärkischen Landesregierung, Graz, Austria

5 ¹⁶ VIDO-Intervac, Saskatoon, SK, Canada

6

7 Corresponding author: Herman W. Barkema, E-mail: barkema@ucalgary.ca

Summary

In the last decades, many regional and country-wide control programs for Johne's disease (JD) were developed due to associated economic losses, or because of a possible association with Crohn's disease. These control programs were often not successful, partly because management protocols were not followed, including the introduction of infected replacement cattle, because tests to identify infected animals were unreliable, and uptake by farmers was not high enough because of a perceived low return on investment. In the absence of a cure or effective commercial vaccines, control of JD is currently primarily based on herd management strategies to avoid infection of cattle and restrict within farm and farm-to-farm transmission. Although JD control programs have been implemented in most developed countries, lessons learned from JD prevention and control programs are underreported. Also, JD control programs are typically evaluated in a limited number of herds and the duration of the study is less than 5 y, making it difficult to adequately assess the efficacy of control programs. In this manuscript, we identify the most important gaps in knowledge hampering JD prevention and control programs, including vaccination and diagnostics. Secondly, we discuss directions that research should take to address those knowledge gaps.

Keywords: Johne's disease, *Mycobacterium avium* subspecies *paratuberculosis*, control, prevention

1 **Introduction**

2

3 Johne's disease (JD) is an infectious chronic inflammatory disorder of the intestine

4 in ruminants caused by *Mycobacterium avium* subspecies *paratuberculosis* (MAP). It is a

5 major health problem, resulting in intermittent diarrhea, loss of body condition, and lower

6 productivity (e.g. Tiwari et al., 2006). In the terminal phase, which most animals will not

7 reach due to premature culling, animals die in very poor body condition. Infected

8 ruminants shed MAP in manure and milk in increasing quantities as the disease

9 progresses (Whitlock and Buergelt, 1996). The disease is widespread in domestic and

10 wild ruminant populations in almost all countries in the world and causes great economic

11 losses, not only because of lower productivity, but also as a result of loss of future

12 income due to premature culling (McKenna et al., 2006b; Garcia and Shalloo, 2015). The

13 herd-level prevalence of MAP infection is likely >50% in most countries with a

14 substantial dairy industry (Barkema et al., 2010). In the absence of control measures, JD

15 typically spreads, as farms often purchase cattle, frequently from herds with unknown JD

16 status. In a recent review, Garcia and Shalloo (2015), reported substantial losses due to

17 MAP infection, which escalate as the within-herd MAP prevalence and incidence of

18 clinical JD cases increase. In Canada, the economic damage caused by JD was estimated

19 at \$50 CAN per cow per year in MAP-infected herds, resulting in an average loss per

20 infected farm of nearly \$3,000 CAN annually (Chi et al., 2002; Tiwari et al., 2008).

21 Raizman et al. (2009) estimated the income over feed cost losses at \$366 per MAP-

22 shedding cow per lactation, whereas Bhattarai et al. (2014) estimated a loss of \$1,644 US

1 per 100 cows in a herd with a true prevalence of 7%. The cost of the disease to the US
2 cattle industry was estimated at \$250M US per year (Ott et al., 1999).

3 Meta-analyses have demonstrated that the association of MAP with Crohn's disease
4 in humans is specific and cannot be denied (Feller et al., 2007; Abubakar et al., 2008),
5 although a causal role has not yet been demonstrated (Waddell et al., 2015; Waddell et al.,
6 2016). Furthermore, transmission from cattle to humans has never been proven. However,
7 addressing JD worldwide should be considered a proactive step in ensuring consumer
8 confidence if a link were to be established between JD and Crohn's disease.

9 The epidemiology of JD is very different among cattle, sheep and goats. These
10 species have very distinct differences when it comes to the course of MAP infection;
11 therefore, inferences from one species cannot be naively applied to other species.
12 Production type (e.g. dairy versus beef) also has a role in the course of MAP infection.
13 This is not only evident in cattle (dairy versus beef), but probably even more evident in
14 sheep and goats (i.e., wool/meat producing sheep in Australia and milk producing
15 sheep/goats in the Mediterranean).

16 In this manuscript, we identify the most pressing gaps in knowledge hampering
17 JD prevention and control programs (summarized in Table 1). Secondly, we discuss
18 directions that research should take to solve these knowledge gaps.

20 **Control programs**

21
22 Due to economic losses, and its possible association with Crohn's disease, many
23 control programs for JD have been developed worldwide. Many of these programs

1 focused on MAP-infected herds and were based on testing and culling test-positive cows,
2 plus management adaptations (Benedictus, 1984; Collins, 1994; Rossiter et al., 1996;
3 Kennedy, 2001). The focus of some other programs was to identify MAP-negative herds
4 with the aim of keeping these herds, and in the case of Australia, Norway, and Sweden an
5 entire region negative, and also having them as a source of MAP-negative replacement
6 animals (e.g. Kalis et al., 2004; Kennedy et al., 2011; Frössling et al., 2013; Whist et al.,
7 2014). Tests included delayed type hypersensitivity (skin) tests, serological tests, direct
8 detection of MAP by microscopy, and using culture or polymerase chain reaction (PCR)
9 to detect MAP in fecal samples. Presently, fecal culture is considered the most sensitive
10 and specific ante-mortem test to identify MAP infection (Kalis et al., 2002; Whitlock et
11 al., 2000). However, as individual fecal culture is expensive and time consuming, most
12 JD control programs use ELISAs to detect potentially infected animals (e.g. Lavers et al.,
13 2014). Another reason for using ELISAs is that the extent of shedding correlates well
14 with the ELISA titers (Dargatz et al., 2001), hence culling ELISA-positives may be an
15 effective and relatively low-cost option for removing high shedders. Currently, fecal
16 culture is often replaced with direct PCR on feces (e.g., Plain et al., 2014; Laurin et al.,
17 2015).

18 JD control programs have been implemented in most developed countries, with
19 objectives based on the national economic situation of the cattle, sheep and goat industry
20 and the herd-level prevalence of MAP infection (reviewed by Kennedy, 2011; Geraghty
21 et al., 2014). In general, objectives include: 1) prove and protect freedom of disease at the
22 country, regional or farm-level, e.g. in Norway (Whist et al., 2014), Sweden (Frössling et
23 al., 2013), and northern and western Australia (Kennedy, 2011); 2) protect export of milk

1 or genetics, e.g. Canada (McKenna et al., 2006a); 3) decrease prevalence of MAP
2 infection and limit farm-level economic losses, e.g. Denmark (Nielsen et al., 2007), the
3 UK (Pritchard et al., 2017), Ireland (McAloon et al., 2016) and the USA (Wells et al.,
4 2008); 4) eliminate or reduce MAP load in bulk milk, e.g. the Netherlands (Weber and
5 van Schaik, 2007); and 5) eliminate MAP infection, e.g. Norway in goats (Nagel-Alne et
6 al., 2014).

7 Some factors that hampered the success of such control programs were lack of
8 compliance with management protocols, use of tests with a sufficiently high sensitivity to
9 identify infected cattle, persistence of MAP in the environment, inadequate test
10 frequency, appearance of unexpected new infections, and purchase of replacement
11 animals causing new introductions (Benedictus, 1984; Collins, 2001). A complementary
12 modeling study showed that consistent application of preventive measures was key to
13 success, although only “test and cull” was not crucial to control JD (Groenendaal et al.,
14 2003). However, “test and cull” can support and hasten elimination of infection from a
15 herd that also has good management practices (Kudahl et al., 2011). Because there is no
16 cure and, except for sheep, there are no vaccines that effectively prevent MAP infection,
17 control of JD is currently based primarily on herd management strategies that reduce the
18 risk of infection in young calves and restrict within-farm and farm-to-farm transmission.
19 Additionally, control programs that include testing of individual animals, in general
20 advise culling of MAP-positive animals.

21 Although JD control programs have been implemented in most developed
22 countries, the lessons learned from the actual experience with JD prevention and control
23 programs are underreported worldwide. JD control programs are typically evaluated in a

1 small number of herds (e.g. Collins et al., 2010; Pillars et al., 2011) and many cattle
2 control programs have not included beef cattle. Additionally, particularly in cattle, results
3 of a JD control program can only be judged after at least 5 y (Caldow and Gunn, 2001;
4 Nielsen and Toft, 2011), although most of the current well-designed programs have been
5 implemented that long (Table 1). Except for goats in Norway (Nagel-Alne et al., 2014),
6 no report could be found of a herd in which MAP infection has successfully been
7 eradicated (Table 1). There are many explanations for this failure which are discussed in
8 the following sections.

9 Finally, some programs were implemented but abandoned due to the outbreak of
10 another disease (e.g. Bovine Spongiform Encephalopathy or Foot-and-Mouth Disease) or
11 loss of funding (e.g. USA and Alberta, Canada), making it difficult to regain trust and re-
12 institute the program.

14 **Prevalence**

16 It is essential that reliable estimates of disease prevalence (animal or herd level)
17 are available since this will determine how to proceed and monitor the results of a control
18 program over time. The goals may vary from eradication in areas of low prevalence,
19 control in areas with high prevalence, or increased surveillance in an area with no prior
20 history of disease. Prevalence estimates obtained by surveys are affected by test accuracy;
21 therefore, comparisons among studies must be adjusted to better estimate the true
22 prevalence.

1 Infection with MAP and cases of JD have been reported from all continents with
2 ruminant populations. Prevalence in most regions is currently unknown, and prevalence
3 studies have low design uniformity, making comparisons among regions unreliable due to
4 different sampling strategies and case definitions. Additionally, in most studies, the true
5 herd- and animal-level prevalence has not been estimated. Thus, the results of these
6 studies and the reported prevalence estimates of MAP infection can currently not be
7 compared directly (Table 1). Additionally, in most regions, herd and animal-level
8 prevalence are underestimated, as the sensitivity of ELISAs is overestimated, particularly
9 for cattle in 1st lactation heifers (McKenna et al., 2005a,b; Nielsen and Toft, 2008).
10 Almost invariably, in regions where herd-level prevalence estimates were obtained using
11 an ELISA and independently validated using fecal culture or environmental culture, true
12 prevalence estimates (adjusted for test characteristics) are much lower based on testing
13 with ELISA versus culture (e.g. Lavers et al., 2014; Wolf et al., 2014). Although MAP
14 test comparisons have been the subject of many studies, there is a lack of studies
15 comparing test characteristics in populations that reflect the target population when
16 estimating prevalence of MAP infection (Nielsen and Toft, 2008). The sensitivity of
17 MAP tests increases in dairy cattle with increasing days in milk and age but decreases
18 with increased milk yield (Eisenberg et al., 2015b; Kirkeby et al., 2015), whereas
19 sensitivity increases with age in sheep and goats (Lybeck et al., 2011). Therefore,
20 sensitivity estimates need to be adjusted for age in all ruminants, and days in milk and
21 milk yield in dairy cattle when comparing between or within herds and also over time.

22 Comparing prevalence over time, among regions and countries is often unreliable
23 due to the use of a variety of diagnostic tests, often with unknown or unreliable test

1 **characteristics**. To compare herd- and animal-level prevalence estimates of MAP among
2 countries, and to allow for the development of international trade standards, we
3 recommend a supranational standardized study, comparable to a *Neospora caninum*
4 seroprevalence study involving cattle from 4 countries (Bartels et al., 2006) **(Table 1)**.
5

6 **The Pathogen**

7

8 Strain typing is useful in helping to clarify epidemiological and virulence
9 questions that cannot otherwise be resolved; however, limited genetic variation among
10 MAP isolates **within host species** has slowed progress. Several typing techniques have
11 been used (Collins and de Lisle, 1986; Coffin et al., 1992; Whittington et al., 1998;
12 Whittington et al., 2000; Motiwala et al., 2003; Amonsin et al., 2004; Thibault et al.,
13 2007). Whole-genome sequencing (WGS), because of its higher resolution, is the logical
14 evolution of technology to assist epidemiological investigations and control programs.
15 The cost of WGS still has to decrease though for this technique to become the technique
16 of choice in this kind of studies.

17 Variable number tandem repeat (VNTR) and mycobacterial interspersed repetitive
18 unit (MIRU) typing have been moderately successful for characterizing MAP isolates.
19 Diversity among isolates has been reported based on VNTR typing (Thibault et al., 2008;
20 Stevenson et al., 2009; Fritsch et al., 2012; Sohal et al., 2014), with most isolates being 1
21 of 2 dominant VNTR types. MIRU-VNTR genotyping does not, however, accurately
22 reflect phylogenetic relationships, and repeat sequences are subject to homoplasy
23 (Ahlstrom et al., 2014; Bryant et al., 2016). Current VNTR typing includes loci that are

1 too unstable and unreliable to be used for a molecular epidemiological analysis of MAP
2 (Ahlstrom et al., 2015). Short sequence repeat (SSR) typing (Amonsin et al., 2004)
3 further differentiates MAP isolates of the same VNTR type (Stratilo et al., 2006; Thibault
4 et al., 2008) but lacks sufficient discrimination and stability for epidemiological studies
5 (Kasnitz et al., 2013). Nevertheless, in specific cases, VNTR (with or without SSR
6 typing) can still be useful for supporting source tracing investigations and JD control
7 measures (Oakey et al., 2014).

8 Whole-genome sequencing (WGS) provides unparalleled detail regarding genetic
9 profiles of MAP. Genomic epidemiology of MAP is new (Ahlstrom et al., 2015; 2016)
10 but has already provided important insights into transmission dynamics. Single nucleotide
11 polymorphisms (SNPs) identified through WGS are evolutionarily stable and can be
12 reliably used to identify true evolutionary relationships (Pearson et al., 2009). In a MAP-
13 endemic environment, this level of detail is invaluable in understanding the molecular
14 epidemiology and transmission dynamics. For example, there are at least 8 genetically
15 distinct MAP subtypes in Canadian dairy cattle, with > 80% of isolates belonging to a
16 single dominant subtype (Ahlstrom et al., 2016). However, this information cannot be
17 extrapolated to other countries because dominant strains vary between countries and
18 continents (Whipple et al., 1990; Machackova et al., 2004; Motiwala et al., 2004;
19 Kiehnbaum et al., 2005). Some strains may be more successful in spreading or persisting
20 in different environments or management systems. It is difficult to know whether high
21 MAP prevalence within a specific herd relates to a high MAP infection opportunity (e.g.
22 poor biosecurity) or is due to MAP strains with increased transmission potential on these
23 farms.

1 Strain typing can be used to track transmission of MAP in a variety of settings and
2 host species. Studies of within-herd spread of MAP infection (Pradhan et al., 2011),
3 between-herd transmission (Oakey et al., 2014), and the role of wildlife in spreading
4 MAP (Fritsch et al., 2012) require molecular tools that can differentiate MAP types.
5 WGS was recently used to identify multiple mixed genotype infections (Davidson et al.,
6 2016); these infections could affect disease dynamics and impact pathogen evolution and
7 genetics and thereby impact the efficacy of therapeutic treatments or vaccines (Table 1).

8 An understanding of the full genetic diversity of MAP is needed to accurately
9 assess subtype-specific phenotypes and virulence characteristics, and to develop vaccines
10 and effective management practices (Table 1). Investigations into strain-specific
11 differences in MAP virulence and pathogenicity have been mostly limited, however, to
12 major strain types (Janagama et al., 2006; Motiwala et al., 2006; Gollnick et al., 2007;
13 Borrmann et al., 2011), with significant differences between Types I and II isolates
14 reported for growth rates and intracellular survival (Table 1).

15 Investigations have determined phenotypic differences among MAP subtypes for
16 a variety of traits, including growth rates and invasion efficiencies, immunogenicity,
17 virulence as measured by macrophage invasion efficiencies and kinomic responses
18 (Whittington et al., 2011; Griebel et al., 2014). Future vaccine development and
19 molecular epidemiological studies should also consider the relative frequencies of MAP
20 subtypes with a focus on dominant subtypes. There are differences among MAP strains in
21 the immune response that they stimulate, as well as differences in host tropism, disease
22 phenotypes and ability to evade control by vaccines (Sohal et al., 2010; Colavecchia et
23 al., 2016) (Table 1).

1

2 **Tests**

3

4 **Purpose of testing**

5

6 Test results used in control programs should primarily assist decision makers
7 achieve a specific objective. Furthermore, the specific test strategies employed are likely
8 to differ between regions, depending on the logistics of implementation and other
9 practicalities, as well as herd size (Dorshorst et al., 2006). Identification of infected
10 animals before they spread the infection while still maximizing the life-time production
11 of an animal is the goal of a cost-effective test strategy. Purposes of testing primarily
12 include: 1) estimate infection prevalence to determine the best course of action; 2)
13 minimize financial losses as a result of impaired milk production or growth and increased
14 culling rate; 3) estimate the effects of proposed control measures or evaluate additional
15 measures or management changes; 4) eliminate infectious cattle to reduce spread of
16 infection, 5) reduce the risk of MAP contamination of food products for human
17 consumption; and 6) eradicate MAP from a herd (or region). Tests for these purposes can
18 focus on individual animals, herds, or a subset of the herd. Control strategies that focus
19 on the individual animal and target specific management conditions contributing to
20 transmission include: 1) identification of infectious animals actively shedding MAP; and
21 2) identification of infected animals at risk of shedding MAP (Table 1).

22 Ideal tests used for control should identify the infectious animal or predict its
23 infectivity. However, since we do not know the infectious dose of MAP, shedding

1 patterns of infected animals, and factors contributing to disease progression, it is difficult
2 to interpret test results (Table 1). Consequently, we struggle to identify MAP infection
3 cases and non-cases, which is essential when evaluating the accuracy of diagnostic tests.
4 This has resulted in decades of reported test evaluations that are of questionable quality
5 (Nielsen and Toft, 2008).

6 Existing tests are performing reasonably well in detecting advanced stages of JD,
7 although the specificity of test results may be challenged and the number of bacteria
8 excreted in feces or milk is rarely quantified. Detection of early-stage infection is only of
9 interest for a control program if these animals then become infectious (Marcé et al.,
10 2011). Otherwise, these infections may disappear from a specific population. However,
11 because the sensitivity of diagnostic tests in calves is generally low, young stock are
12 rarely tested for MAP. As a result, no longitudinal studies have been published that
13 followed infected calves or lambs and confirm how many subsequently test positive
14 (Table 1).

16 Early-stage diagnostics

18 Early stage diagnostics primarily target pro-inflammatory immune responses. To
19 be useful, however, they should differentiate infected from recovered animals (Dennis et
20 al., 2011) and indicate if or when an animal will become infectious (de Silva et al., 2013).
21 Whereas detection of fecal shedding by direct extraction followed by a MAP-specific
22 PCR can detect if an animal is infectious (Fock-Chow-Tho et al., 2017), it cannot indicate

1 whether or when it will become infectious. Such a test would likely be useful to achieve
2 eradication in low prevalent populations (Table 1).

3 Identification and multiplexing of antigens that elicit an early humoral immune
4 response could yield a serological test that overcomes the current delay in antibody-based
5 detection of MAP infection. Analyses of longitudinal serum samples (from
6 experimentally infected calves) were used to detect developing humoral immune
7 responses against MAP proteins (Bannantine et al., 2008), with anti-MAP antibodies
8 detected as early as 70 d after infection. Novel MAP antigens for detection of antibody
9 responses in subclinical cattle were also reported (Facciuolo et al., 2013).

10 The interferon-gamma (IFN- γ) assay detects cell-mediated immune responses to
11 early-stage MAP infection (Stabel, 2000), but needs improvements and standardization as
12 differences in composition of the purified protein derivative (PPD) antigens can influence
13 specificity (Kalis et al., 2003; Capsel et al., 2016). Single proteins to increase specificity
14 of T-cell responses are being sought (Huygen, 2014; Carlos et al., 2015; Leite et al.,
15 2015; Rana et al., 2015). Blood samples must be tested within 8 h for optimal results to
16 ensure T-cell viability, although IL-12 and anti-IL-10 supplementation (Mikkelsen et al.,
17 2012) or IL-7 and IL-12 supplementation (Plain et al., 2012) can increase the interval to
18 48-hour interval before testing. Ultimately, an on-farm test would be most effective.

19 Leukocyte markers associated with MAP infection may also be used as a
20 diagnostic test. For example, increased expression of CD25 and CD45RO on T cells may
21 be an early indication of infection (Stabel and Robbe-Austerman, 2011), but these
22 markers lack specificity. Furthermore, phenotype analysis of leukocytes is again
23 dependent upon the isolation and analysis of viable cells. The lack of useable and rapid

1 diagnostic tests for specific biomarkers is clearly a bottleneck in identifying animals with
2 MAP infection.

3 To accommodate the discovery of biomarkers that can predict the onset of the
4 infectious stage, experimental infection models presenting a natural disease outcome (e.g.
5 Begg et al., 2010; Mortier et al., 2013) are essential for test development (Hines et al.,
6 2007; Begg and Whittington, 2008). Ultimately, longitudinal sampling of herds with
7 different prevalence profiles is necessary to validate the outcomes of experimental
8 infections in an unbiased and representative set of samples from infected but not yet
9 infectious animals.

10 11 **Late-stage diagnostics**

12
13 Late-stage diagnostic tests detect anti-inflammatory immune responses, e.g.
14 ELISAs detecting IgG1. They are relatively well characterized and easy to automate, but
15 sensitivity is in general still low compared to viral infections, such as bovine leukosis
16 (Nielsen and Toft, 2008). Ideally, these should be reliable point-of-care tests using blood
17 or milk from individual cows (Lavers et al., 2014) (Table 1). Better characterization of
18 disease progression in relation to the induction of IgG1 antibody responses is desired.

19 There might be value in detection of immunoglobulin isotypes other than IgG
20 (e.g. IgM and IgA) (Table 1). Although IgM is the first isotype to appear in response to
21 an infection, this response has limited applicability as it is transient (Abbas and Riemann,
22 1988). Isotype switching results in local mucosal production of IgA and anti-MAP IgA
23 responses have been detected in fecal samples from infected sheep (Begg et al., 2015).

1 The challenge remains the identification of individual MAP proteins that detect
2 antibodies specific to MAP and not environmental *Mycobacterium* spp.

3 Calves, kids and lambs were reported to be ELISA-positive for MAP 3 to 4 mo
4 after infection (Storset et al., 2001; Kurade et al., 2004; Mortier et al., 2015a). However,
5 in very young animals, such ELISA antibodies may be an indication of passive immunity
6 (transfer of colostrum-derived maternal antibodies), as maternal antibodies reacting with
7 MAP were detected in serum collected from calves up to 121 d of age (Schillinger et al.,
8 2013).

9 The titer of an ELISA is predictive for the probability of MAP shedding (Weber
10 and Van Schaik, 2007). This association renders the utility of an ELISA as highly
11 applicable to JD control in dairy herds when the aim is to reduce transmission by
12 selective removal of shedders. In that instance, an ELISA may replace fecal culture or
13 PCR but it is then important to shorten the testing interval (Lu et al., 2008).

14 15 **Herd-level diagnostics**

16
17 Environmental sampling is a quick sampling method to determine the MAP
18 infection status of a herd (Wolf et al., 2017). However, this sampling method is only
19 sufficiently sensitive in relatively intensive livestock operations such as housed dairy
20 cattle. In extensive farming, such as sheep and cow-calf herds in many countries,
21 environmental sampling currently does not have sufficient sensitivity (Whittington et al.,
22 2003). For example, culture followed by PCR on 6 environmental samples detected 70%
23 of MAP-infected dairy herds (Wolf et al., 2015a). Samples collected from alleyways of

1 lactating cow pens and manure lagoons were most sensitive (Wolf et al., 2015a). On
2 farms with only manure piles (or if an outdoor lagoon is inaccessible due to weather),
3 additional samples should be collected from indoor manure pits or alleyways. In a recent
4 German study in cow-calf herds, environmental samples collected in high cow traffic
5 areas at the end of the winter had a sensitivity of 64% (Klawonn et al., 2016), which is
6 similar to housed dairy herds (Wolf et al., 2017). There is certainly room for
7 improvement of environmental sampling; modifications in the number of collected
8 samples per set and in sampling intervals may result in more accurate diagnostic
9 protocols (Table 1). Further refinements of environmental sampling, including
10 determining impact of season, are needed (Wolf et al., 2015a). Culture of pooled fecal
11 samples, most often consisting of pools of 5 or 10 for cattle, or 10 to 50 for sheep fecal
12 samples, has been extensively evaluated and proven to be relatively sensitive
13 (Whittington et al., 2000a; Sergeant et al., 2002; Van Schaik et al., 2007; Verdugo et al.,
14 2014b).

15 Processing pooled environmental samples with direct PCR instead of culture
16 reduces processing time and costs (Boelske and Herthnek, 2010). An additional
17 advantage of PCR compared to culture is, that PCR is not dependent on viable MAP
18 bacteria in the sample. That might result in a higher sensitivity with PCR, especially if
19 samples are collected in the winter, or at locations where manure accumulates over
20 extended times. Test characteristics for PCR (typically using IS900 or F57 as the target)
21 relative to culture have been reported, with overall good results (e.g. Cook and Britt,
22 2007; Clark et al., 2008; Fock-Chow-Tho et al., 2017) for both pooled and environmental

1 samples (e.g. Kawaji et al., 2007; Mita et al., 2016). Results are, however, highly depend
2 on the extraction method and the primer(s) used (Mita et al., 2016) (Table 1).

3 Testing of bulk tank milk or a pool (whole herd set of Dairy Herd Improvement
4 milk samples) using a commercial ELISA is an inexpensive method of herd screening for
5 JD in dairy cattle (Kelton et al., 2014). To determine a herd's MAP infection status, bulk
6 milk samples can either be analyzed for the presence of MAP-specific antibodies using
7 ELISA, or for the presence of MAP bacteria using direct PCR. Although repeated bulk
8 tank test results are consistent over short intervals and correlated with herd prevalence
9 (Nielsen and Toft, 2014), results can be influenced by herd size and within-herd
10 prevalence of ELISA-positive individuals. This testing identifies herds with moderate
11 (>5% within-herd milk ELISA-positive) to high (>8% within-herd milk ELISA-positive)
12 prevalence (Serraino et al., 2014). This test is not sensitive enough to detect low
13 prevalence herds (Jayarao et al., 2004; Van Weering et al., 2007; Khol et al., 2013) or to
14 monitor subtle changes in within-herd prevalence over time.

15 As is the case with all JD testing strategies, given the low sensitivity of the tests,
16 the proportion of infected herds is underestimated and negative test results can give dairy
17 producers a false sense of security based on the belief that a negative test means their
18 herd is uninfected. However, with increasing frequency statistical tools such as Bayesian
19 statistics are used to correct for less than ideal test characteristics that are predominantly
20 the result of the biology of MAP infection (e.g. Verdugo et al., 2014; McAloon et al.,
21 2016).

22
23 **Recent developments and future directions**

1

2 Novel findings and approaches in diagnostic test development and evaluations are
3 rare, and so far no major breakthroughs have been provided. Mostly, incremental
4 improvements to existing tests and test strategies have been identified, e.g. repeated
5 testing in a Danish JD control program (Nielsen, 2008). Once prevalence is reduced, cost-
6 effective monitoring of the MAP status of a population can be difficult. Development of
7 cost-effective strategies for surveillance and certification are still required while retaining
8 a focus on the fit-for-purpose criterion (OIE, 2012).

9 Quantitative PCR (qPCR) for assessing the number of MAP bacteria in feces has
10 great promise in comparison to bacterial culture (Christopher-Hennings et al., 2003;
11 Khare et al., 2004; Kralik et al., 2012; Laurin et al., 2015) (Table 1). This technique has
12 been validated on spiked fecal samples and proficiency panels, including fecal samples
13 from naturally infected animals (e.g. Plain et al., 2014). This approach is strongly
14 dependent on efficient DNA extraction, which has been studied (summarized in Bölske
15 and Herthnek, 2010). However, quantification by qPCR is still only a relative method
16 because a standard curve of spiked samples needs to be used to determine the
17 approximate copy number of MAP organisms in a test sample. Digital (third-generation)
18 PCR, is expected to be more quantitative, more precise and predict absolute numbers of
19 shed bacteria in feces and therefore be useful to validate other tests and biomarkers as has
20 been studied for *Mycobacterium tuberculosis* (Devonshire et al., 2016). microRNAs
21 circulating in blood may provide another a promising method to detect MAP infection
22 (Shaughnessy et al., 2015), but this has not been confirmed.

1 The effect of MAP genotype on disease progression, shedding, immune responses
2 or generation of other biomarkers is not well characterized (Table 1). A longitudinal
3 follow-up of animals by ELISA, IFN- γ testing, fecal culture and eventually tissue culture
4 is needed.

5 Using proteomic and transcriptomic analyses, several putative biomarkers for
6 early infection with MAP have been proposed (Skovgaard et al., 2006; Seth et al., 2009;
7 Casey et al., 2011; Zhong et al., 2011; You et al., 2012; David et al., 2014a, b;
8 Thirunavukkarasu et al., 2014; Shin et al., 2015). Metabolomic profiling detected MAP
9 infection earlier than other diagnostic methods, with individual metabolites distinguishing
10 infected from non-infected cattle (De Buck et al., 2014). Furthermore, changes in fecal
11 microbiota of MAP-infected cattle may have promise for identifying infected animals
12 during subclinical stages of JD (Derakshani et al., 2015). Analysis of volatile organic
13 compounds emitted during culture may assist in identifying growth and also strain
14 identification (Trefz et al., 2013). These and other emerging diagnostic technologies and
15 approaches have recently been reviewed by Britton et al. (2016). Unfortunately, none of
16 these biomarkers have been properly validated on naturally infected cattle of varying ages
17 or in various stages of infection to reveal their true sensitivity and specificity (Britton et
18 al., 2016) (Table 1).

20 **Routes of transmission**

21
22 MAP can be transmitted by: 1) ingestion of fecal material, 2) drinking
23 contaminated colostrum or milk, 3) intrauterine infection and, potentially, 4) aerogenic

transmission. The best method to prevent transmission is expected to be limiting exposure of calves to adult feces by systematic separation of adult cows and calves, in combination with good hygiene practices (Marcé et al., 2011).

There are limited data regarding the quantity of bacteria shed by animals in the different infection stages (Marcé et al., 2010; Whittington et al., 2000b), with substantial inter- and intra-animal variability (Whitlock et al., 2000; Crossley et al., 2005). However, recent advances in PCR technologies (digital droplet PCR; Pinheiro et al., 2012) should enable a determination of the exact number of organisms associated with the different modes of transmission (feces, milk, colostrum) for all different stages of infection (susceptible/uninfected, transiently infectious, latently infected, infectious, resistant stages) (Table 1). This knowledge would be especially meaningful if in parallel the corresponding infectious dose and the corresponding infection risk associated with the various transmission routes were determined for animals of all ages. However, it is important to note that single inoculations may be a poor model of natural infection as the frequency of exposure might be an important factor in transmission. Typically, several or consecutive-day inoculations are used (Hines et al., 2007; Begg et al., 2010). However, a trickle dose (limited numbers of organisms) was highly effective in causing intestinal infection (Eisenberg et al., 2011), suggesting that more complex dynamics play a role during natural infections and need to be taken into account for a better understanding of transmission and infection.

Colostrum

1 Milk and colostrum can be contaminated with MAP, either through fecal
2 contamination of teats or shedding from the udder (Sweeney et al., 1992; Streeter et al.,
3 1995; Stabel and Goff, 2004). In a Danish study, calves that received colostrum from
4 multiple cows had 1.24 times the odds of testing MAP ELISA-positive as adults
5 compared to cows that only received colostrum from their dam (Nielsen et al., 2008). In
6 contrast, the risk of infection from ingestion of colostrum was recently challenged in a
7 cohort study concluding that MAP-contaminated colostrum did not increase the risk of
8 MAP shedding in calves up to two years of age (Eisenberg et al., 2015a). This reveals a
9 knowledge gap regarding transmission and certainly the relative contribution of some
10 transmission routes (Table 1).

11 A reduction of within-herd prevalence of MAP infection may be achieved by
12 pasteurizing colostrum to reduce MAP transmission. Heat treatment reduces the number
13 of viable MAP bacteria in milk (Lund et al., 2002; Eltholth et al., 2009). However, most
14 studies used huge numbers of bacteria, spiked milk (not naturally infected), milk instead
15 of colostrum and a hot water bath, not a commercial pasteurizer. Therefore, the current
16 knowledge is insufficient to answer the question whether on-farm pasteurization using
17 commercial pasteurizers can effectively reduce the number of viable MAP bacteria in
18 colostrum (Table 1).

20 **Calf-to-calf**

21
22 Cattle farmers typically try to interrupt fecal-oral transmission by implementing
23 best-hygiene management practices. In many studies, there were associations between

1 specific management practices and the likelihood of animals being infected with MAP
2 (e.g. Nielsen and Toft, 2011); however, many questions remain unanswered. In particular,
3 the potential risk of calf-to-calf transmission is largely overlooked in JD prevention and
4 control programs; only 1 of 8 MAP modeling studies included calf-to-calf transmission
5 (reviewed by Marcé et al., 2010) (Table 1). Although many researchers associate a low
6 risk with this potential transmission pathway, based on the assumption that calves will
7 not shed MAP in their feces (Groenendaal et al., 2002; Marcé et al., 2011), there is strong
8 evidence of calves being infected by other calves (Wells and Wagner, 2000; Benedictus
9 et al., 2008; van Roermund et al., 2007). One reason for these apparently discordant
10 results is the difficulty in establishing an exposure-disease relationship, due to the
11 delayed clinical onset of JD (Collins, 1996). Benedictus et al. (2008) reported that calf-to-
12 calf transmission occurs, and that contact with infectious animals increases the likelihood
13 of calves being infected with MAP, which supports previous data (van Roermund et al.,
14 2007). Unfortunately, this study (Benedictus et al., 2008) was done on a single farm and
15 outcomes were measured long after exposure. Consistent with some studies (Bolton et al.,
16 2005; Weber et al., 2006b; van Roermund et al., 2007; Santema et al., 2012), in a recent
17 challenge experiment on age- and dose-dependent susceptibility (Mortier et al., 2013),
18 47% of calves with a proven MAP infection shed the bacterium at least once from 2 to 6
19 mo after infection (Mortier et al., 2014c). In a recent study, co-mingling MAP-infected
20 and non-infected calves for 3 mo resulted in infection of 50% of the naïve calves (Corbett
21 et al., 2017). It was estimated that under the circumstances of the study, one MAP-
22 infected calf on average infected 3 other calves. Additionally, on 17 MAP-infected dairy
23 farms in Alberta, Canada, 3% of calves were shedding the bacterium and on 9 of these

1 farms, MAP-positive environmental samples were collected from young stock pens (Wolf
2 et al., 2015b). Due to acidified milk feeding and automatic milk feeders (Barkema et al.,
3 2015), many dairy calves are group-housed both before and after weaning. Consequently,
4 there is a need for longitudinal studies quantifying the risk of MAP transmission among
5 calves by measuring MAP shedding, environmental contamination, and tissue-levels in
6 naturally infected calves (Table 1). If calf-to-calf transmission is deemed important, JD
7 prevention and control programs will require modifications.

9 **Intra-uterine**

11 Some calves from MAP-infected cows are infected at birth (reviewed by
12 Whittington and Windsor, 2009). Intrauterine infection is more likely in cows with
13 clinical JD (Whittington and Windsor, 2009), and may be lower in herds with a low MAP
14 prevalence (Adaska and Whitlock, 2012). Most studies that determined the proportion of
15 intrauterine infection with MAP recovered fetuses of MAP-infected cows at various
16 stages of pregnancy (Whittington and Windsor, 2009). Since many of these fetuses were
17 recovered prior to term, the proportion of calves born with a MAP infection is
18 undoubtedly underestimated. Additionally, it is not known if or when intrauterine
19 infected calves will start shedding, how infection progresses, and the nature of the
20 immune response, compared to calves infected orally soon after birth (Table 1). The rate
21 of 15% intra-uterine infections may have been over-estimated as a new analysis
22 suggested it may only be 4% (Mitchell et al., 2015).

Intrauterine transmission from dam to fetus appears to be more common in red deer than in cattle and sheep, with 90% of clinically affected hinds having an infected fetus (van Kooten et al., 2006). In another study, MAP was isolated from 78% of fetuses from 18 subclinically infected seropositive red deer hinds (Thompson et al., 2007). By contrast, MAP was isolated from only 39% of fetuses from clinically affected dairy cows and 9% of fetuses from subclinically infected cows (Whittington and Windsor, 2009). In sheep, intrauterine transmission is thought to occur in <10% of infected ewes. Intrauterine transmission of MAP has also been detected in free-ranging red deer and chamois (Deutz et al., 2005). As in cattle, MAP infected colostrum and milk may cause pseudo-vertical transmission in deer and other wildlife.

Environment

If a cow is shedding MAP in the feces, her manure is infectious and can remain so for at least 1 y (Whittington et al., 2004; Whittington et al., 2014). The proportion of environmental manure samples that are culture-positive increases with an increasing prevalence of MAP-infected cows (Wolf et al., 2015a). In sheep, shedding is dose- and age-at-infection dependent (McGregor et al., 2012). However, sheep of all ages and exposed at all doses are equally likely to be colonized by MAP, although the severity of histopathological lesions was strongly determined by age at exposure (McGregor et al., 2012). These findings stress the role of transmission at pasture, especially for young animals.

1 There is a need for more research to investigate the role of environmental
2 transmission taking into account the survival characteristics of MAP and the contact
3 structure between animals in a herd (Table 1). Survival of MAP in the environment has
4 been suggested to depend on many factors, including soil pH, fecal content,
5 concentrations of macro and micro-nutrients (e.g., Fe, Mo, and Cu), temperature, and
6 exposure to sunlight (reviewed by Elliott et al., 2015). No viable (culturable) MAP was
7 detected after 2 mo of anaerobic digestion at a farm-scale biogas plant (Slana et al.,
8 2011). MAP was present in settled dust samples on dairy farms under both experimental
9 and field conditions (Eisenberg et al., 2010a,b). Although current JD prevention programs
10 do not consider dust, it could be a fomite and facilitate transmission (Corner et al., 2004)
11 (Table 1).

12 The results of many of the studies on survival in the environment are very
13 difficult to generalize to different environmental circumstances (Elliott et al., 2015) and
14 MAP strain types (Whittington et al., 2004) (Table 1). Secondly, most studies were done
15 as an experimental model and not as a field study. Also, because it is not clear what dose
16 of viable MAP will lead to infection in animals of different age groups, it is not clear
17 whether ingestion of the surviving concentration of MAP bacteria would actually lead to
18 a MAP infection. Additionally, it is not clear whether these factors only influence
19 survival and/or virulence of MAP bacteria, or whether there might also be an influence on
20 the host, through (in)direct effects of these factors on the immune system (Lugton, 2004).
21 Finally, management practices relevant to the transmission of MAP may be associated
22 with environmental factors such as soil type, exposure to sunlight, and humidity (Table
23 1).

Within-herd transmission

Understanding the routes of MAP transmission between cattle is very important for effective control of the disease. The best-established transmission route of MAP is oral uptake of bacteria by susceptible young stock, via colostrum, milk, water or food contaminated with feces from MAP-shedding animals (Sweeney, 1996; Benedictus et al., 2008). In addition, intra-uterine transmission has been described (see above).

Although isolation of adult cattle from young calves has an important role in prevention of JD (Groenendaal et al., 2002), after 20 y of management and hygiene measures to prevent MAP transmission in a dairy herd, complete eradication was not achieved, implicating other non-identified and therefore non-controlled transmission routes (Table 1). In sheep, experimental intratracheal introduction of MAP caused infection (Kluge et al., 1968), whereas intestinal infection occurred after exposure to MAP-containing aerosols given intratracheally and intranasally (Eisenberg et al., 2011). Since MAP has been detected in bioaerosols on dairy farms, transmission of MAP by bioaerosols should be further studied including estimations of the relative contributions of the various transmission routes identified. Additionally, there is evidence that infection of non-lactating heifers or adult cows can occur (e.g. Fecteau et al., 2010), likely when infection pressure is high.

All existing recommendations (McKenna et al., 2006a) for decreasing the risk of new infections of MAP in a dairy operation are meant to reduce infection rates in calves

1 by decreasing contact with adult cows. Regardless, a better understanding of transmission
2 and increased testing should improve disease control (Table 1).

3 4 **Between-herd transmission**

5
6 Introduction of infected animals is the most important route of transmission of
7 MAP between herds (Rangel et al., 2005). Frequent cattle purchases from other herds
8 without knowledge of their disease status increased the risk for MAP culture-positive
9 environmental samples (Wolf et al., 2016). Although testing animals pre-purchase will
10 prevent introduction of positive animals, the long incubation period will result in many
11 false-negative cattle. Thus, herd-level testing of the herd of origin in a certification-and-
12 surveillance program (Weber et al., 2004; Weber et al., 2006a) is likely to be more
13 effective in reducing the risk associated with trade of cattle between herds. Although
14 MAP can survive for a long time in water (Elliott et al., 2015), the role of transmission
15 through surface and drinking water is not known, and there are many unknowns about the
16 role of transmission from other ruminants and wildlife to domestic ruminants (see below)
17 (Table 1).

18 19 **Between-species transmission**

20
21 Cross-grazing sheep and deer reduces the risk of clinical paratuberculosis in deer
22 because the sheep strain of MAP is less pathogenic for deer than the cattle strain (Heuer
23 et al., 2012; Verdugo et al., 2014a). Modeling exercises have shown that the similarity of

1 strain types isolated from beef cattle and deer was 3-fold greater when direct contact
2 between these species was considered compared to a scenario that ignored the contact
3 structure. Transmission would be expected to go in both directions between co-grazed
4 animals, thus grazing infected deer with sheep or cattle puts both species at risk. In the
5 UK, the presence of farmed deer increased the risk of reporting clinical JD in dairy cattle
6 kept on the same farm (ORs ranged from 15 to 209; Cetinkaya et al., 1997).

7 In many areas, there is co-grazing of wildlife and domestic livestock, which may
8 allow cross-infection to occur under specific conditions (high animal density, neonates in
9 population, etc.). In an alpine region in Italy, MAP-infected ibex are sympatric with
10 seropositive cattle (Ferroglio et al., 2000). In Spain, cattle, sheep, and goats share
11 pastures and waterholes with herds of fallow deer in which paratuberculosis has been
12 diagnosed (Balseiro et al., 2008). In Germany, it appears that feral and farmed animals
13 are reservoirs for specific MAP genotypes (Fritsch et al., 2012). Although other studies
14 failed to demonstrate significant transmission between wildlife and livestock, false-
15 negatives can be common. It is important to keep in mind that many wildlife studies have
16 limited observations and with that, limited power (Table 1). Also, there is no uniformity
17 in MAP-diagnostics which makes it challenging to compare studies from around the
18 world (Table 1).

20 **Role of wildlife**

21
22 A better understanding of the epidemiology of MAP in wildlife is essential for
23 implementing effective disease prevention and infection control programs for livestock.

1 MAP has been recovered from a wide variety of wildlife species worldwide (with or
2 without signs of JD). Mostly it has been found in wild ruminants (reviewed by
3 Mackintosh and Griffin, 2010); however, other species such as lagomorphs may have an
4 important role in MAP transmission (reviewed by Hutchings et al., 2010). Regardless,
5 much remains to be learned about the distribution of MAP among free-ranging wildlife
6 populations, impacts of infection on the health of these populations, potential for these
7 populations to act as reservoirs for MAP, and the extent of MAP transmission between
8 wildlife and livestock in various environments (Table 1).

9 For most wildlife surveillance efforts, resources are scant. Current methods that
10 reduce the cost of diagnostic testing, such as pooled fecal culture, have only been
11 validated for cattle (van Schaik et al., 2007). Commercially available ELISA tests require
12 validation prior to their use for MAP surveillance in specific wildlife species (Pruvot et
13 al., 2013). Furthermore, it is difficult to sample wildlife populations, particularly to obtain
14 high-quality random samples, which negatively affects the quality of diagnostic results.

15 Although it has never been quantified, transmission from wildlife is considered a
16 very low risk. Regardless, the livestock industry has opportunities to mitigate the
17 likelihood of inter-species interactions; covering feed storage, keeping wildlife away
18 from forage feeders and other attractants on the farm, and fencing ponds reduced the
19 frequency with which wildlife visit livestock premises (Van Campen and Rhyan, 2010).
20 The livestock industry could be motivated to pro-actively keep wildlife away from
21 livestock if there were well-documented financial benefits. There is limited information
22 available on disease introductions of endemic pathogens through wildlife (Table 1), and
23 most published models focus on introductions of emerging and notifiable diseases with

1 huge financial impact (e.g. tuberculosis and foot and mouth disease).

2 The main limitation in considering the role of wildlife species is understanding
3 the circulation of MAP at the livestock-wildlife interface and identifying elements that
4 allow certain wildlife populations to maintain MAP infection and potentially act as a
5 reservoir for livestock. Certainly, it should not be assumed that sympatric wildlife and
6 domestic cattle populations always exchange infection (e.g. Whittington et al., 2001).
7 Increased knowledge on these aspects of the epidemiology of MAP would contribute to
8 our understanding of infection dynamics and may improve JD control programs (Table
9 1). Unfortunately, with current limited funding opportunities for wildlife-focused studies,
10 as well as the challenges of designing appropriate multidisciplinary studies, these answers
11 might not be easily generated.

12 Studies to date investigating the possibility of interspecies MAP transmission
13 involving wildlife have focused simply on the presence or absence of shared strains.
14 None have analyzed the degree, directionality of transmission, or incidence of infection
15 caused by spillback or spill-over. Therefore, a genotyping scheme with an appropriate
16 level of discriminatory power, implemented within a well-designed sampling scheme, is
17 essential for reliably investigating the role of wildlife in the epidemiology of MAP
18 (Fritsch et al., 2012) (Table 1).

20 **Susceptibility**

22 **Age**

Dairy calves are exposed to MAP by the manure from infected adult cattle that shed the bacteria and contaminate water and feed (McKenna et al., 2006a). Greater permeability of the neonatal intestine facilitated MAP entry (Sweeney, 1996), whereas there was increased resistance with age due to repeated exposure to the organism (Delgado et al., 2013) and the dilution effect of the growing rumen (Windsor and Whittington, 2010). However, in an experimental infection trial with 50 calves inoculated at 2 wk, 3, 6, 9, or 12 mo of age, calves were equally susceptible to infection with MAP up to 1 y of age, based on antibody production, fecal shedding, IFN- γ response, pathology, and tissue culture (Mortier et al., 2013; Mortier et al., 2014a; Mortier et al., 2014b; Mortier et al., 2014c; Mortier et al., 2015b). Additionally, infection of non-lactating heifers (1 to 2 y old) occurred when grazing on pasture contaminated with MAP (Fecteau et al., 2010). Therefore, although susceptibility of MAP infection clearly decreases with increasing age (Windsor and Whittington, 2010), control programs should, depending on the purpose of the program, consider including cattle of all ages (Table 1).

Although likely animals of all ages can be infected with MAP, age at infection seems to affect immune responses, fecal shedding, and lesions at necropsy. Calves inoculated at 3 mo of age shed more frequently, had a more robust humoral immune response, and more severe lesions at necropsy than calves inoculated at an older age, or at the same age but with a low dose (Mortier et al., 2014a; Mortier et al., 2014b). The cellular immune response was less marked in calves inoculated at 2 wk of age than calves inoculated later in life (Mortier et al., 2014c), consistent with the need for a strong cellular immune response to confer better protection against infection (Stabel, 2006). In sheep, age of exposure also strongly affected the outcome of MAP infection, with lambs

1 infected earlier in life starting to shed sooner, having more severe pathology and higher
2 mortality rate (McGregor et al., 2012).

3 A strong initial cellular immune response, possibly in combination with humoral
4 immunity, appeared to be key to controlling progression of JD (Stabel, 2006). Therefore,
5 infection at a young age when the immune system is still immature and less effective
6 (Chase et al., 2008) generally caused more severe lesions. Therefore, age at the time of
7 infection affected the consequences of MAP infection. In a study analyzing shedding
8 patterns in naturally infected cows, it was clear that the majority of studied cows never
9 developed high shedding levels (Mitchell et al., 2015). Those that did, typically never
10 reduced their shedding level to low or no shedding. Cows that eventually became high
11 shedders had a pattern of continuous shedding. In contrast, cows with an intermittent
12 shedding pattern had a low probability to ever become high shedders. In addition, cows
13 that start shedding at a younger age (less than three years of age) have a lower hazard of
14 becoming high shedders compared to cows starting to shed at an older age. These data
15 suggest the presence of three categories of immune control. Cows that are intermittent
16 shedders have the infection process under control (no progressive infection). Cows that
17 start shedding persistently at a young age partially control the infection, but eventually
18 will be high shedders (slow progressive infection), whereas cows that start shedding
19 persistently at an older age cannot effectively control the infection and become high
20 shedders rapidly (Mitchell et al., 2015). However, little more is known about factors
21 influencing the course of MAP infection.

22 23 **Heritability of susceptibility and resistance**

1

2 Quantitative genetic studies predominantly performed in Holstein-Friesian cows
3 have demonstrated that genetics play an important role in susceptibility to JD, and their
4 heritability estimates indicate that the genetic basis of JD is likely a multigenic trait
5 (Koets et al., 2000; Gonda et al., 2006). Channel Island **cattle** breeds are 1.4 to 8.3 times
6 more likely to test positive for MAP compared to other dairy breeds (Cetinkaya et al.,
7 1997; Norton et al., 2009; Sorge et al., 2011). Outbreaks of JD occur in beef herds, but
8 prevalence of MAP infection is much lower than in dairy herds. *Bos indicus* purebreds
9 and crossbreeds have odds ratios 17-fold and 3.5-fold greater than *Bos taurus* breeds for
10 positive ELISA results (Roussel et al., 2005). Despite likely differences due to
11 management (intensively farmed housed dairy cattle vs. extensively beef cattle kept on
12 large pastures), the lower prevalence in beef cattle may also be the result of lower genetic
13 susceptibility of some beef cattle breeds (**Table 1**). Genetics as an approach to disease
14 control is an emerging discipline. Identifying the genetic basis of the lower susceptibility
15 will provide possibilities for selection for resistance to MAP infection in dairy and beef
16 cattle, as has been done with Red deer (Dobson et al., 2013). While genetic improvement
17 for disease resistance is slow, the results are permanent (Kirkpatrick and Shook, 2011;
18 van Hulzen et al., 2014). There is good evidence in a range of ruminant species for
19 genetic influence on susceptibility to mycobacterial infections (Kirkpatrick and Shook,
20 2011).

21 Heritability of test-positivity for MAP infection in cattle ranges from 0.041 to
22 0.159 (Koets et al., 2000; Gonda et al., 2006; Hinger et al., 2007; Attalla et al., 2010; van
23 Hulzen et al., 2011) indicating that part of the variability in response to exposure in the

1 population is due to genetics (Table 1). Multiple recent studies also clearly suggest that
2 susceptibility to MAP infection is multigenic or polygenic. The effect of genetic
3 polymorphisms in candidate genes was recently reviewed (Kirkpatrick and Shook, 2011)
4 as well as linkage analysis of genetic susceptibility using genome-wide association
5 studies (GWAS; Purdie et al., 2011). Limited congruence between studies was attributed
6 to: 1) definitions of case and control; 2) phenotypic data recorded (tissue culture, fecal
7 culture, blood ELISA, milk ELISA); and 3) variability in diagnostic methods used
8 between cattle at the same stage of infection.

9 The host response to MAP can be categorized as susceptible, resistant or tolerant.
10 Attempts to locate loci associated with resistance to paratuberculosis have proven to be
11 more challenging than finding loci associated with susceptibility. A major problem for
12 investigating the influence of genetics on susceptibility against MAP infection is the
13 difficulty in accurately classifying susceptible, resistant or tolerant animals. For example,
14 it is yet unknown whether selection against ELISA-positivity results in offspring more
15 resistant to (progression of) the infection, or in offspring that is unable to mount an
16 ELISA response given infection.

17 There is also an inherent uncertainty in phenotypes, due to the low sensitivity of
18 diagnostic tests for MAP infection. Heritability estimates for resistance to JD are higher
19 when fecal culture is used versus ELISA (Kupper et al., 2012). Possible genetic
20 influences on host immunological responses could be a confounding factor (Table 1).

21 A comprehensive GWAS study (Settles et al., 2009) identified genetic loci
22 associated with 4 phenotypes: presence of MAP in the tissues, presence in feces, presence
23 in both tissues and feces, and presence in tissues but not in feces. Based on identification

1 of loci associated with these groups, distinct loci may be important to specific stages of
2 the disease. As different genes are associated with different steps in the infection and
3 disease processes, it is expected that different diagnostics will identify different
4 susceptibility genes corresponding to the observed phenotype. Misclassification can be
5 avoided to some extent by parallel test interpretation.

6 So far, the IFN- γ assay has not been applied in genetic linkage studies. While it is
7 debatable whether a positive test corresponds with active MAP infection or is only
8 evidence of exposure, it is likely that, in combination with other diagnostics, this
9 additional information would help identify different phenotypes, particularly the resistant
10 type (Table 1). Ideally, other biomarkers (e.g. transcriptomics) would be used to identify
11 susceptible animals. For this purpose, biomarker outcomes need to be analyzed with
12 knowledge of the genetic make-up of exposed animals.

13 Consolidation of marker-assisted breeding approaches for protection of animal
14 populations against paratuberculosis is the ultimate goal of genetic studies. Animal
15 selection based on marker-assisted breeding might lead to cattle populations with
16 enhanced disease resistance and favorable vaccine responses by stimulating protective
17 immune responses (Fisher et al., 2011). However, before these markers can be used to
18 guide selection, undesirable genetic linkages need to be identified. Such a
19 counterproductive linkage occurred when high milk production was genetically
20 associated with slightly increased susceptibility to MAP (Shook et al., 2012). In addition,
21 genetic linkage studies can be expanded from identifying direct associations with
22 susceptibility to infection to associations (e.g. likelihood of progression to clinical

disease, specific responses to vaccination, or tendency to progress to supershedding)
(Table 1).

It is not surprising that studies of genetic influence on JD susceptibility of cattle have not had consistent outcomes (Table 1). Apparent causes include size of the study, population structures, markers used and case definitions. Because cattle populations often have a high level of relatedness, the hidden presence of closely related animals in a sample would cause an *a priori* unequal distribution of allele frequencies between cases and controls, which could inflate the rate of false-positive associations between trait and marker (Minozzi et al., 2012). This calls for collaborative cross-border experimental designs, use of appropriate statistical models when analyzing genetic data, and awareness of the genetic structure of the population under study. An initial combined analysis of 2 distinct populations, in which different phenotypic definitions were used, resulted in discovery of novel putative genetic markers for susceptibility (Minozzi et al., 2012).

Future case-control studies should consider limitations of diagnostic tests and lack of knowledge on the family structure of the study objects. However, alternatives to case control studies exist and involve cohort study design (classifying animals according to genotype), with disease outcome being determined after a period sufficient for signs/tests of disease to become apparent and be accurately determined in a longitudinal study (Purdie et al., 2011). Regardless, large numbers of animals are needed to detect small differences in susceptibility due to specific gene loci.

Now that multiple SNPs have been associated with susceptibility to MAP infection, a series of follow-up experiments are important next steps, the so-called post-GWAS functional characterization of susceptibility variants. Detailed molecular studies

1 to determine the function of the specific nucleotide substitutions mechanistically should
2 follow. Next, experimental infection trials with specific genotypes could be envisioned
3 which would investigate actual effects on infection dose, susceptibility age, diagnostic
4 outcomes, immune responses, immune cell profiles, etc. (Table 1).

5 Much effort has been spent identifying a connection between host genotype and
6 susceptibility to MAP infection. However, a portion of the variation in disease
7 manifestation and progression might also be correlated with different MAP genotypes
8 (Table 1). Perhaps specific MAP genotypes associate with a specific host genotype.
9 However, such multilevel genotype linkage analyses have not been done.

11 **Vaccination**

12
13 The Gudair® vaccine has been widely applied in Australian sheep herds and has
14 become the dominant JD control practice. Using this killed vaccine reduced prevalence of
15 MAP infection and fecal shedding, and mortality in Australian sheep herds considerably
16 (Reddacliff et al., 2006; Dhand et al., 2016). This vaccine does not prevent MAP
17 infection, and can therefore not be used on its own to eradicate MAP infection. In
18 contrast to sheep, in cattle no effective vaccine is available, and the lack of an efficacious
19 vaccine that protects against infection with MAP is hampering control programs. Existing
20 JD cattle vaccines can reduce clinical impacts of infection, including sometimes reduced
21 shedding, but they do not prevent infection. Additional obstacles are interference with
22 tests to identify animals infected with other mycobacterial species (e.g. *M. bovis*) and that
23 they can cause severe reactions at the injection site (Kalis et al., 2001). Therefore, there is

1 clearly a need for better vaccines in addition to improved diagnostic tests for JD (Table
2 1).

3 Ideally, a MAP vaccine would protect against infection, keeping negative herds
4 MAP-free and safeguard young and susceptible animals in high-prevalence herds.
5 Arguably, such an ideal vaccine could be live attenuated, can be administered orally, is
6 sufficiently virulent to trigger protective cell-mediated immune responses, protects
7 exposed animals against infection at the tissue level, is cleared relatively quickly from the
8 vaccinated animal, can be differentiated from wild type strains, is not spread to other
9 animals, protects against homologous and heterologous strains, and generates immune
10 responses that can be differentiated from *M. bovis* infections and ideally also from natural
11 MAP infections (with appropriate diagnostic tests).

12 Current vaccines may partially reduce infectiousness or shedding load, prolong
13 the latent period of infected animals, slow progression from low- to high-shedding, or
14 decrease the cumulative incidence of clinical JD cases; however, they are not effective in
15 preventing infection (Kormendy, 1992; Wentink et al., 1994; Kalis et al., 2001;
16 Kathaperumal et al., 2008; Rosseels and Huygen, 2008; Romano and Huygen, 2009;
17 Santema et al., 2009; Alonso-Hearn et al., 2012). Bacterin vaccines, subunit vaccines
18 (Koets et al., 2006; Hoek et al., 2010; Thakur et al., 2013; Faisal et al., 2013) and vector
19 vaccines (Roupie et al., 2012; Bull et al., 2014) have also been created, but have been less
20 effective than expected. Their inability to prevent establishment of infection leaves the
21 potential for infected animals to break with disease if protective immunity wanes. Subunit
22 vaccines have been reported to provide incomplete protection in murine models (Stabel et
23 al., 2012) or ruminant models (calves and goats) of infection (Koets et al., 2006;

1 Kathaperumal et al., 2008; Kathaperumal et al., 2009). In addition, other subunit vaccines
2 (Gurung et al., 2013; Facciulo and Mutharia, 2014; Johnston et al., 2014) are being
3 proposed as having potential to prevent infection. Most vaccines have been tested in a
4 preventive pre-exposure setting. However, as calves are commonly born into herds with
5 endemic MAP infection and a MAP contaminated environment post-exposure strategies
6 should also be considered (Santema et al., 2013).

7 Globally, most current vaccines are based on MAP strain 316F formulated in
8 mineral oil adjuvant, either as a live (Neoparasec) or dead strain (Mycopar, ID-Lelystad,
9 Gudair, Silirum). Only Mycopar is licensed in the US and used on only 5% of US dairy
10 operations (Cho et al., 2012) and under strict control of local veterinary authorities, as
11 vaccinated cattle are more likely to be false-positive on a standard bovine tuberculosis
12 test (Muskens et al., 2002). The single intradermal tuberculin test is still the most widely
13 used tuberculosis diagnostic test in cattle (Bastida and Juste, 2011). However,
14 modification of the test, whereby 2 sites are injected with either tuberculin from *M. bovis*
15 or MAP and a difference in reactivity is recorded, has already been shown to solve the *M.*
16 *bovis* interference problem in the vast majority of cases. This comparative intradermal
17 tuberculin test has been available for many years and is an official test according to OIE
18 and EU legislation (Bastida and Juste, 2011). So, false-positive *M. bovis* detection can be
19 eliminated when next-generation vaccines are accompanied by compatible diagnostics
20 (Table 1).

21 A critical aspect in development of MAP vaccines is the protective immune
22 responses they are supposed to elicit. The precise nature of a protective immune response
23 is still to be determined (Table 1). An advantage of live-attenuated vaccines (LAV) is that

1 they will stimulate both cell-mediated and humoral immune responses (Park et al., 2011;
2 Faisal et al., 2013). Cell-mediated immune responses have been associated with
3 protection (Stabel et al., 2011; Settles et al., 2014), and therefore it has been postulated
4 that if a LAV MAP vaccine could drive the immune response to a proinflammatory Th1
5 profile and prevent a shift to the humoral Th2 response, it might be more effective in
6 delaying disease progression (Coussens, 2004; Stabel et al., 2011). In sheep, specific
7 lymphocyte subsets play a role in protecting against MAP infection, including sheep
8 vaccinated with killed vaccine (de Silva et al., 2015). Although LAV induced strong
9 protection in a mouse model (Ghosh et al., 2015), in a goat model they showed no
10 protective efficacy in some studies (Hines et al., 2014; Park et al., 2014) and strong
11 reduction in shedding in a recent other study (Shippy et al., 2017); they have apparently
12 not been tested in cattle.

13 The appropriate level of attenuation of LAV strains has not been established
14 (Table 1). However, it is clear from past experiences that these models should not be
15 restricted to *in vitro* experimentation or mouse models (Bannantine et al., 2014).
16 Furthermore, single knock-out strains may not be optimal vaccine candidates because
17 they may not be attenuated enough to stimulate the protective immune response without
18 causing disease. Although a 1-gene knock-out (KO) might yield a strain that cannot
19 persist in the animal and/or environment and therefore not pose an infectious risk to
20 spread and cause disease, a second attenuation should be introduced to eliminate the
21 manipulative mechanisms that inhibit or counteract protected immune responses. So, a
22 vaccine strain should not only trigger protective immune responses but also avoid
23 immune modulation pathways to be activated, which will allow a wild type (WT) strain

1 to establish an infection and ensure that the immune evasion strategies of MAP are
2 rendered neutral.

3 Selection of the first type of essential gene can be done by screening transposon
4 mutant libraries for an optimal LAV (Rathnaiah et al., 2014; Wang et al., 2014), ideally
5 in a ruminant host. However, selection of the second type of KO requires further study of
6 pathogenesis in *in vitro* and *in vivo* models. We need a better understanding of the
7 immune evasion and immune modulation strategies that MAP clearly is capable of
8 (Arsenault et al., 2014) (Table 1). Due to these immune evasion properties, MAP can
9 subvert both the induction of acquired immune responses and cell-mediated responses.
10 Reasons for these are potentially twofold: first, because the LAV vaccine will have
11 retained these immune evasion properties and therefore elicit inadequate immune
12 responses; and secondly, because an infecting WT strain will be able to subvert immune
13 responses generated by a vaccine. A future protective vaccine may need to prevent or
14 counteract these evasion mechanisms.

16 **Diagnostic aspects of vaccination**

18 Differentiation of Infected and Vaccinated Animals (DIVA) is an important
19 consideration. When using a subunit vaccine approach, DIVA can be obtained as has
20 been shown in cattle vaccinated with a subunit vaccine against MAP (Santema et al.,
21 2009). None of the three currently commercially available killed vaccines or LAV lend
22 themselves well to DIVA, although engineered vaccine strains might be better.
23 Complementary diagnostics will have to be developed to incorporate DIVA in an

1 integrated platform of new diagnostic and vaccination strategies, particularly to
2 differentiate *M. bovis* infections from JD vaccination (Table 1). Next-generation
3 diagnostics for MAP infection will likely measure early cell-mediated immune responses.
4 Immune responses against this positive marker of extraneous nature would clearly
5 demonstrate that animals were vaccinated (Table 1). A negative marker, being an
6 immunodominant antigen that is ‘deleted’ from the vaccine strain, could be implemented
7 in novel *M. bovis* diagnostics next to antigens specific for *M. bovis* (e.g. ESAT-6/CFP-10
8 and Rv3615c) (De Val et al., 2012). Thus, the problematic interference with *M. bovis*
9 testing could be completely mitigated with a marked vaccine and compatible diagnostics.

10 Following complementary diagnostics for DIVA purposes, new biomarkers that
11 act as correlates of protection and/or that indicate lack of protection are necessary for
12 screening, development, and testing of novel MAP vaccine candidates (de Silva et al.,
13 2015). So far, good correlates of protection have remained elusive.

14 From exercises modeling impacts of imperfect MAP vaccines, it was concluded
15 that vaccination should be integrated into a comprehensive control program that includes
16 test-and-cull intervention and improved calf rearing management (Bush et al., 2008; Cho
17 et al., 2012). Cost-benefit analysis of vaccination against MAP in dairy cattle was
18 performed (Groenendaal et al., 2015). Vaccination was beneficial by reducing the
19 frequency of heavy shedders and clinically affected animals. A meta-analysis also
20 concluded that vaccination against MAP is a valuable tool in reducing MAP
21 contamination risks and reducing or delaying production losses (Bastida and Juste, 2011).

22 Newly developed vaccines will need to be well-characterized to fully understand
23 their risks and benefits. For example, the risk of shedding in vaccinated cattle needs to be

1 investigated, as was done in sheep vaccinated with the Gudair vaccine (Windsor et al.,
2 2014).

3 The success of a LAV vaccine will depend on which MAP strain is selected to
4 generate the vaccine (~parent strain). Vaccine strains will likely have to be sufficiently
5 homologous in antigen composition with the majority of field strains. In India, a vaccine
6 based on a regional strain variant was more effective than a commercial JD vaccine
7 (Singh et al., 2013). In our view, there should be a focused effort to characterize the
8 diversity of MAP strains (Table 1). Genotypic and phenotypic variation needs to be
9 investigated to derive quantitative and qualitative understanding of this diversity around
10 the world.

11 12 **Uptake**

13
14 Nearly all JD prevention and control programs worldwide are voluntary and their success
15 depends on enrollment and retention, along with sufficient uptake of recommended best
16 management practices. To establish high participation rates, JD control programs need to account
17 for farmers' motivators and barriers to enroll and implement recommended management changes
18 (Table 1). In recent years, farmers' "mindset" and its influence on behavior has become an
19 important focus of research (e.g., Derks et al., 2012; Jansen and Lam, 2012; Garforth, 2015;
20 Roche et al., 2015). Farmers' attitudes and beliefs toward the disease and the proposed approach
21 for disease control have important roles in their motivation to adhere to suggested management
22 strategies (Ritter et al., 2017). This relatively new avenue of research has important implications
23 for our approaches to motivating individual farmers to adopt optimal JD management practices.

1 Farmers' considerations such as improved herd health and concern over consumer health can be
2 important motivators to participate in JD control or certification programs (Kovich et al., 2006;
3 Nielsen, 2011; Roche et al., 2014). External incentives can also be an important driver to control
4 MAP; a decision analysis from the farmers perspective indicated that a milk-price differentiation
5 of only € 0.005/kg milk was sufficient to make enrollment of Dutch dairy farmers in a control
6 program attractive (Velthuis et al., 2006). However, management constraints (e.g. limited time or
7 finances) and the perceived complexity of JD control programs can be critical impediments for
8 uptake of biosecurity measures (Rossiter and Burhans, 1996; Wraight et al., 2000; Sorge et al.,
9 2010), and often farmers prefer to "wait-and-see" how the JD control program works on other
10 farms before they enroll (Ritter et al., 2015) (Table 1).

11 Several studies reported that farmers rely on various sources to obtain their farm
12 management information and should be approached according to their specific needs to ensure
13 successful knowledge uptake (Heffernan et al., 2008; Jansen et al., 2010; Russell and Bewley,
14 2011). In particular, herd health veterinarians have been regarded as trustworthy and reliable
15 sources of advice on disease and disease risk management (Ellis-Iversen et al., 2010; Brennan
16 and Christley, 2013). Because of this key role veterinarians play in farmers' management
17 decisions, it is important to employ them as mediators between industry and farmers. However,
18 veterinary practitioners' attitudes towards JD control are often unknown and the extent to which
19 they actively promote enrollment in JD control programs and/or individual on-farm changes to
20 reduce MAP transmission remains unclear (Table 1). Even farmers provided with veterinary
21 advice on JD control often implemented less than half of the suggestions made (Wraight et al.,
22 2000; Sorge et al., 2010). Miscommunication between dairy practitioners and farmers is likely an
23 important cause of the lack of uptake. For example, veterinarians did not assess producers'

1 expectations sufficiently but provided them with too many, potentially overwhelming,
2 suggestions (Sorge et al., 2010). These apparent gaps in veterinary-farmer communication need
3 to be addressed.

4 More recent applied research has investigated best practices for communicating
5 with producers and motivating on-farm change, often employing group-based and peer
6 learning approaches. Many of these efforts have emphasized the importance of the
7 veterinarian for making tailored on-farm recommendations, but have also promoted the
8 use of facilitators to better understand and respond to producer mindset. Recent examples
9 from Australia (Kingham and Links, 2012), Denmark (Trier et al., 2012), and Canada
10 (Roche et al., 2015) have yielded promising results for motivating on-farm change
11 towards effective JD prevention and control.

12 In addition to a lack of knowledge regarding the discussion of JD control with
13 producers, communication strategies used to inform decision makers in government and
14 policy authorities, farmer organizations, and breeding associations are still unclear.
15 Researchers' responsibility is to provide information that enable evidence-based
16 decisions, for example regarding JD certification and trade regulations. Clear
17 communication between researchers, farmer organizations, and authorities creating
18 evidence-based policy will likely increase motivation to initiate and continue control
19 programs and improve policy acceptance and uptake by farmers.

20 Johne's disease is only one of many fecal-orally transmitted infectious diseases in
21 cattle. Measures to prevent infection with MAP will likely also have positive effects on
22 the incidence of infection with *Salmonella* spp., *Cryptosporidium parvum* and
23 *Cryptosporidium bovis*, *Escherichia coli*, and rota- and corona virus (McKenna et al.,

2006b). Often, the latter bacteria cause more obvious clinical signs than MAP and convince the farmer of the presence and severity of illness. These “cues-to-action” might enhance farmers’ openness to improve suboptimal management practices. Therefore, addressing calf health and biosecurity more holistically could help motivate producers that currently do not perceive JD control as high priority (Table 1).

Conclusions

Nearly a century of JD control programs has, particularly in the dairy industry, not resulted in sufficient progress. Except for goats in Norway, no reports can be found of a herd in which MAP infection has been eradicated, and in many countries, herd- and animal-level prevalence has not decreased. As a result, JD continues to cause considerable losses to the livestock industry. The insufficient progress has been the result of gaps in our knowledge about this difficult disease. Research has focused on test development and evaluation, vaccine development, and design and evaluation of management strategies to prevent MAP infection. Many of the knowledge gaps identified are in these areas (Table 1). However, the authors are optimistic that if sufficient progress can be made addressing these knowledge gaps, progress in the control of this insidious disease in the next decades will be better. The introduction of a JD vaccine has made a huge impact in the Australian sheep industry. Development of a JD vaccine with accompanying diagnostic tests that prevents infection and shedding and does not impair tuberculosis diagnostics remains 1 of the most pressing gaps for the livestock industry. Reliably and pro-actively (pre-shedding) identifying infected animals that will very likely

shed the pathogen, potentially involving biomarkers, is another research priority. Susceptibility for MAP infection differs among breeds. Identification of genetic markers that distinguish very susceptible from more resistant animals has the potential to advance JD control. Quantification of the role of calf-to-calf transmission will be necessary to improve cattle control programs. Uptake of JD control programs will improve if these knowledge gaps have been satisfactorily addressed. However, because of the voluntary nature of JD programs, it will still be important to identify factors that motivate farmers to enroll in these programs.

Acknowledgements

The origins of this manuscript are in the disease and product analysis conducted for Johne's disease in the DISCONTTOOLS project (<http://www.discontools.eu>).

References

- Abbas, B., Riemann, H.P., 1988. IgG, IgM and IgA in the serum of cattle naturally infected with *Mycobacterium paratuberculosis*. Comp. Immunol. Microbiol. Infect. Dis. 11, 171-175.
- Abubakar, I., Myhill, D., Aliyu, S.H., Hunter, P.R., 2008. Detection of *Mycobacterium avium* subspecies *paratuberculosis* from patients with Crohn's disease using

1 nucleic acid-based techniques: a systematic review and meta-analysis. *Inflamm.*
2 *Bowel Dis.* 14, 401-410.

3 Adaska, J.M., Whitlock, R.H., 2012. Low rate of detectable in utero transmission of
4 *Mycobacterium avium* subspecies *paratuberculosis* in a dairy herd with a low
5 prevalence of Johne's disease. *J. Vet. Diagn. Invest.* 24, 153-155.

6 Ahlstrom, C., Barkema, H.W., De Buck, J., 2014. Improved short-sequence-repeat
7 genotyping of *Mycobacterium avium* subspecies *paratuberculosis* by using
8 matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl.*
9 *Environm. Microbiol.* 80, 534-539.

10 Ahlstrom, C., Barkema, H.W., Stevenson, K., Zadoks, R.N., Biek, R., Kao, R., Trewby,
11 H., Haupstein, D., Kelton, D.F., Fecteau, G., Labrecque, O., Keefe, G.P.,
12 McKenna, S.L.B., De Buck, J., 2015. Limitations of variable number of tandem
13 repeat typing identified through whole genome sequencing of *Mycobacterium*
14 *avium* subsp. *paratuberculosis* on a national and herd level. *BMC Genomics* 16,
15 161.

16 Ahlstrom, C., Barkema, H.W., Stevenson, K., Zadoks, R.N., Biek, R., Kao, R., Trewby,
17 H., Haupstein, D., Kelton, D.F., Fecteau, G., Labrecque, O., Keefe, G.P., McKenna,
18 S.L.B., Tahlán, K., De Buck J., 2016. Genome-wide diversity and phylogeography
19 of *Mycobacterium avium* subsp. *paratuberculosis* in Canadian dairy cattle. *PLoS*
20 *ONE* 11, e0149017.

21 Alexander, D.C., Turenne, C.Y., Behr, M.A., 2009. Insertion and deletion events that
22 define the pathogen *Mycobacterium avium* subsp. *paratuberculosis*. *J. Bacteriol.*
23 191, 1018–1025.

1 Alonso-Hearn, M., Molina, E., Geijo, M., Vazquez, P., Sevilla, I.A., et al., 2012.
2 Immunization of adult dairy cattle with a new heat-killed vaccine is associated with
3 longer productive life prior to cows being sent to slaughter with suspected
4 paratuberculosis. J. Dairy Sci. 95, 618-629.

5 Amonsin, A., Li, L.L., Zhang, Q., Bannantine, J.P., Motiwala, A.S., Sreevatsan, S.,
6 Kapur, V., 2004. Multilocus short sequence repeat sequencing approach for
7 differentiating among *Mycobacterium avium* subsp. *paratuberculosis* strains. J.
8 Clin. Microbiol. 42, 1694–1702.

9 Arsenault, R.J., Maattanen, P., Daigle, J., Potter, A., Griebel, P., Napper, S., 2014. From
10 mouth to macrophage: mechanisms of innate immune subversion by
11 *Mycobacterium avium* subsp. *paratuberculosis*. Vet. Res. 45, 54.

12 Attalla, S.A., Seykora, A.J., Cole, J.B., Heins, B.J., 2010. Genetic parameters of milk
13 ELISA scores for Johne's disease. J. Dairy Sci. 93, 1729-1735.

14 Balseiro, A., García Marín, J.F., Solano, P., Garrido, J.M., Prieto, J.M., 2008.
15 Histopathological classification of lesions observed in natural cases of
16 paratuberculosis in free-ranging fallow deer (*Dama dama*). J. Comp. Pathol. 138,
17 180-188.

18 Bannantine, J.P., Waters, W.R., Stabel, J.R., Palmer, M.V., Li, L., Kapur, V., Paustian,
19 M.L., 2008. Development and use of a partial *Mycobacterium avium* subspecies
20 *paratuberculosis* protein array. Proteomics. 8, 463-474.

21 Bannantine, J.P., Everman, J.L., Rose, S.J., Babrak, L., Katani, R., Li, L.L., Kapur, V.,
22 Sreevatsan, S., 2014. Evaluation of eight live attenuated vaccine candidates for

1 protection against challenge with virulent *Mycobacterium avium* subspecies
2 *paratuberculosis* in mice. Front. Cell. Infect. Microbiol. 4, 88.

3 Barkema, H.W., Hesselink, J.W., McKenna, S.L.B., Benedictus, G. Groenendaal, H.,
4 2010. Global prevalence and economics of infection with *Mycobacterium avium*
5 subsp. *paratuberculosis* in ruminants. In: Behr, M.A., Collins, D.M. (Eds.),
6 Paratuberculosis: organism, disease, control. CABI. ISBN 9781845936136, pp.
7 10-21.

8 Barkema, H.W., von Keyserlingk, M.A.G., Kastelic, J.P., Lam, T.J.G.M., Luby, C., Roy,
9 J.-P., LeBlanc, S.J., Keefe, G.P., Kelton, D.F., 2015. Invited review: Changes in
10 the dairy industry affecting dairy health and welfare. J. Dairy Sci., 98, 7426-7445.

11 Bartels, C.J., Arnaiz-Seco, J.I., Ruiz-Santa-Quitera, A., Björkman, C., Frössling, J., von
12 Blumröder, D., Conraths, F.J., Schares, G., van Maanen, C., Wouda, W., Ortega-
13 Mora, L.M., 2006. Supranational comparison of *Neospora caninum*
14 seroprevalences in cattle in Germany, The Netherlands, Spain and Sweden. Vet.
15 Parasitol. 137, 17-27.

16 Bastida, F., Juste, R.A., 2011. Paratuberculosis control: a review with a focus on
17 vaccination. J. Immune Based Ther. Vaccines 9, 8.

18 Baumgartner, W., 2013. News concerning paratuberculosis in cattle. Bull. UASVM 70,
19 177-181.

20 Begg, D.J., Whittington, R.J., 2008. Experimental animal infection models for Johne's
21 disease, an infectious enteropathy caused by *Mycobacterium avium* subsp.
22 *paratuberculosis*. Vet. J. 176, 129-45.

1 Begg, D.J., de Silva, K., Di Fiore, L., Taylor, D.L., Bower, K., Zhong, L., Kawaji, S.,
2 Emery, D., Whittington, R.J., 2010. Experimental infection model for Johne's
3 disease using a lyophilised, pure culture, seedstock of *Mycobacterium avium*
4 subspecies *paratuberculosis*. Vet. Microbiol. 141, 301-311.

5 Begg, D.J., de Silva, K., Plain, K.M., Purdie, A.C., Dhand, N., Whittington, R.J., 2015.
6 Specific faecal antibody responses in sheep infected with *Mycobacterium avium*
7 subspecies *paratuberculosis*. Vet. Immunol. Immunopathol. 166, 125-131.

8 Benedictus, A., Mitchell, R.M., Linde-Widmann, A., Sweeney, R., Fyock, T., Schukken,
9 Y.H., Whitlock, R.H., 2008. Transmission parameters of *Mycobacterium avium*
10 subspecies *paratuberculosis* infections in a dairy herd going through a control
11 program. Prev. Vet. Med. 83, 215-227.

12 Benedictus, G., 1984. Evaluation of organized control of bovine paratuberculosis in
13 Friesland province, The Netherlands. Tijdschr. Diergeneeskd. 109, 905-916.

14 Bhattarai, B., Fosgate, G.T., Osterstock, J.B., Fossler, C.P., Park, S.C., Roussel, A.J.,
15 2014. Comparison of calf weaning weight and associated economic variables
16 between beef cows with and without serum antibodies against or isolation from
17 feces of *Mycobacterium avium* subsp *paratuberculosis*. J. Am. Vet. Med. Assoc.
18 243, 1609-1615.

19 Bölske, G., Herthnek, D., 2010. Diagnosis of paratuberculosis by PCR. In: Behr, M.A.,
20 Collins, D.M. (Eds.), Paratuberculosis: organism, disease, control. CABI. ISBN
21 9781845936136, pp. 267-283.

22 Bolton, M.W., Grooms, D.L., Kaneene, J.B., 2005. Fecal shedding of *Mycobacterium*
23 *avium* ssp. *paratuberculosis* in calves: Implications for disease control and

1 management. In: Proc. 8th Int Colloq Paratuberculosis, Copenhagen, Denmark, p.
2 128.

3 Borrmann, E., Möbius, P., Diller, R., Köhler, H., 2011. Divergent cytokine responses of
4 macrophages to *Mycobacterium avium* subsp. *paratuberculosis* strains of Types II
5 and III in a standardized in vitro model. Vet. Microbiol. 152, 101–111.

6 Brennan, M.L., Christley, R.M., 2013. Cattle producers' perceptions of biosecurity. BMC
7 Vet. Res. 9, 71.

8 Britton, L.E., Cassidy, J.P., O'Donovan, J., Gordon, S.V., Markey, B., 2016. Potential
9 application of emerging diagnostic techniques to the diagnosis of bovine Johne's
10 disease (paratuberculosis). Vet. J. 209, 32-39.

11 Bryant, J.M., Thibault, V.C., Smith, D.G., McLuckie, J., Heron, I., Sevilla, I.A., Biet, F.,
12 Harris, S.R., Maskell, D.J., Bentley, S.D., Parkhill, J., Stevenson, K., 2016.
13 Phylogenomic exploration of the relationships between strains of *Mycobacterium*
14 *avium* subspecies *paratuberculosis*. BMC Genomics 26, 79.

15 Bull, T.J., Vrettou, C., Linedale, R., McGuinness, C., Strain, S., McNair, J., Gilbert, S.C.,
16 Hope, J.C., 2014. Immunity, safety and protection of an Adenovirus 5 prime--
17 Modified Vaccinia virus Ankara boost subunit vaccine against *Mycobacterium*
18 *avium* subspecies *paratuberculosis* infection in calves. Vet. Res. 45, 112.

19 Bush, R.D., Windsor, P.A., Toribio, J.A., Webster, S.R., 2008. Financial modelling of the
20 potential cost of ovine Johne's disease and the benefit of vaccinating sheep flocks
21 in southern New South Wales. Aust. Vet. J. 86, 398-403.

1 Caldow, G., Gunn, G.J., 2001. Assessment of surveillance and control of Johne's disease
2 in farm animals in Great Britain. www.defra.gov.uk/animalh/diseases/sac2.PDF
3 (Accessed May 9, 2017).

4 Capsel, R.T., Thoen, C.O., Reinhardt, T.A., Lippolis, J.D., Olsen, R., Stabel, J.R.,
5 Bannantine, J.P., 2016. Composition and potency characterization of
6 *Mycobacterium avium* subsp. *paratuberculosis* purified protein derivatives. PLoS
7 ONE 11, e0154685.

8 Carlos, P., Roupie, V., Holbert, S., Ascencio, F., Huygen, K., Gomez-Anduro, G.,
9 Branger, M., Reyes-Becerril, M., Angulo, C., 2015. In silico epitope analysis of
10 unique and membrane associated proteins from *Mycobacterium avium*
11 subsp. *paratuberculosis* for immunogenicity and vaccine evaluation. J. Theor.
12 Biol. 384, 1-9.

13 Casey, J.L., Sanalla, A.M., Tamvakis, D., Thalmann, C., Carroll, E.L., Parisi, K., Coley,
14 A.M., Stewart, D.J., Vaughan, J.A., Michalski, W.P., Luke, R., Foley, M., 2011.
15 Peptides specific for *Mycobacterium avium* subspecies *paratuberculosis* infection:
16 diagnostic potential. Protein Eng. Des. Sel. 24, 589–596.

17 Cetinkaya, B., Erdogan, H.M., Morgan, K.L., 1997. Relationships between the presence
18 of Johne's disease and farm and management factors in dairy cattle in England.
19 Prev. Vet. Med. 32, 253-266.

20 Chase, C.C., Hurley, D.J., Reber, A.J., 2008. Neonatal immune development in
21 the calf and its impact on vaccine response. Vet. Clin. North Am. Food Anim.
22 Pract. 24, 87-104.

1 Chi, J., VanLeeuwen, J.A., Weersink, A. Keefe, G.P., 2002. Direct production losses and
2 treatment costs from bovine viral diarrhoea virus, bovine leukosis virus,
3 *Mycobacterium avium* subspecies *paratuberculosis*, and *Neospora caninum*. Prev.
4 Vet. Med. 55, 137-153.

5 Cho, J., Tauer, L.W., Schukken, Y.H., Gomez, M.I., Smith, R.L., Lu, Z., Gröhn, Y.T.,
6 2012. Economic analysis of *Mycobacterium avium* subspecies *paratuberculosis*
7 vaccines in dairy herds. J. Dairy Sci. 95, 1855-1872.

8 Christopher-Hennings, J., Dammen, M.A., Weeks, S.R., Epperson, W.B., Singh, S.N.,
9 Steinlicht, G.L., Fang, Y., Skaare, J.L., Larsen, J.L., Payeur, J.B., Nelson, E.A.,
10 2003. Comparison of two DNA extractions and nested PCR, real-time PCR, a new
11 commercial PCR assay, and bacterial culture for detection of *Mycobacterium avium*
12 subsp. *paratuberculosis* in bovine feces. J. Vet. Diagn. Invest. 15, 87-93.

13 Clark, D.L. Jr, Koziczowski, J.J., Radcliff, R.P., Carlson, R.A. Ellingson, J.L., 2008.
14 Detection of *Mycobacterium avium* subspecies *paratuberculosis*: comparing fecal
15 culture versus serum enzyme-linked immunosorbent assay and direct fecal
16 polymerase chain reaction. J. Dairy Sci. 91, 2620-2627.

17 Coffin, J.W., Condon, C., Compston, C.A., Potter, K.N., Lamontagne, L.R., Shafiq, J.,
18 Kunimoto, D.Y., 1992. Use of restriction fragment length polymorphisms resolved
19 by pulsed-field gel electrophoresis for subspecies identification of mycobacteria in
20 the *Mycobacterium avium* complex and for isolation of DNA probes. J. Clin.
21 Microbiol. 30, 1829–1836.

22 Colavecchia, S.B., Fernández, B., Jolly, A., Minatel, L., Hajos, S.E., Paolicchi, F.A.,
23 Mundo, S.L. 2016. Immunological findings associated with Argentinean strains of

1 *Mycobacterium avium* subsp. *paratuberculosis* in bovine models. Vet. Immunol.
2 Immunopathol. 176, 28-33.

3 Collins, D.M., de Lisle, G.W., 1986. Restriction endonuclease analysis of various strains
4 of *Mycobacterium paratuberculosis* isolated from cattle. Am. J. Vet. Res. 47,
5 2226–2229.

6 Collins, D.M., Gabric, D.M., de Lisle, G.W., 1990. Identification of two groups of
7 *Mycobacterium paratuberculosis* strains by restriction endonuclease analysis and
8 DNA hybridization. J. Clin. Microbiol. 28, 1591–1596.

9 Collins, M.T., 1994. Clinical approach to control of bovine paratuberculosis. J. Am. Vet.
10 Med. Ass. 204, 208-210.

11 Collins, M.T., 1996. Diagnosis of paratuberculosis. Vet. Clin. North Am. Food Anim.
12 Pract. 12, 357-371.

13 Collins, M.T., 2001. Prevention of paratuberculosis. Bull. Int. Dairy Fed. 364, 46-53.

14 Collins, M.T., Eggleston, V., Manning, E.J., 2010. Successful control of Johne's disease
15 in nine dairy herds: results of a six-year field trial. J. Dairy Sci. 93, 1638-1643.

16 Cook, K.L., Britt, J.S., 2007. Optimization of methods for detecting *Mycobacterium*
17 *avium* subsp. *paratuberculosis* in environmental samples using quantitative, real-
18 time PCR. J. Microbiol. Methods. 69, 154-160.

19 Corbett, C., De Buck, J., Orsel, K., Barkema, H.W., 2017. Fecal shedding and tissue
20 infections demonstrate transmission of *Mycobacterium avium* subsp.
21 *paratuberculosis* in group-housed dairy calves. Vet. Res. 48, 27.

1 Corner, L.A.L., Pfeiffer, D.U., Abbott, K.A., 2004. The respiratory tract as a hypothetical
2 route of infection of cattle with *Mycobacterium avium* subspecies
3 *paratuberculosis*. Aust. Vet. J. 82, 170-173.

4 Coussens, P.M., 2004. Model for immune responses to *Mycobacterium avium* subspecies
5 *paratuberculosis* in cattle. Infect. Immun. 72, 3089-3096.

6 Crossley, B.M., Zagmutt-Vergara, F.J., Fyock, T.L., Whitlock, R.H., Gardner, I.A., 2005.
7 Fecal shedding of *Mycobacterium avium* subsp. *paratuberculosis* by dairy cows.
8 Vet. Microbiol. 107, 257-263.

9 Dargatz, D.D., Byrum, B.A., Barber, L.K., Sweeney, R.W., Whitlock, R.H., Shulaw,
10 W.P., Jacobson, R.H., Stabel, J.R., 2001. Evaluation of a commercial ELISA for
11 diagnosis of paratuberculosis in cattle. JAVMA 218, 1163-1166.

12 David, J., Barkema, H.W., Mortier, R., Ghosh, S., Luo Guan, L., De Buck, J., 2014a.
13 Gene expression profiling and putative biomarkers of calves 3 months after
14 infection with *Mycobacterium avium* subspecies *paratuberculosis*. Vet. Immunol.
15 Immunopathol. 160, 107-117.

16 David, J., Barkema, H.W., Luo Guan, L., De Buck, J., 2014b. Gene-expression profiling
17 of calves 6 and 9 months after inoculation with *Mycobacterium avium* subspecies
18 *paratuberculosis*. Vet. Res. 45, 96.

19 Davidson, F.W., Ahlstrom, C., De Buck, J., Whitney, H.G., Tahlan, K., 2016.
20 Examination of *Mycobacterium avium* subspecies *paratuberculosis* mixed genotype
21 infections in dairy animals using a whole genome sequencing approach. PeerJ 4,
22 e2793.

1 De Buck, J., Shaykhutdinov, R., Barkema, H.W., Vogel, H.J., 2014. Metabolomic
2 profiling in cattle experimentally infected with *Mycobacterium avium* subsp.
3 *paratuberculosis*. PLoS One 9, e111872.

4 Derks, M., van de Ven, L.M., van Werven, T., Kremer, W.D., Hogeveen, H., 2012. The
5 perception of veterinary herd health management by Dutch dairy farmers and its
6 current status in the Netherlands: a survey. Prev. Vet. Med. 104, 207-215.

7 de Silva, K., Begg, D.J., Plain, K.M., Purdie, A.C., Kawaji, S., Dhand, N.K., Whittington,
8 R.J., 2013. Can early host responses to mycobacterial infection predict eventual
9 disease outcomes? Prev. Vet. Med. 112, 203-12.

10 de Silva, K., Plain, K.M., Begg, D.J., Purdie, A.C., Whittington, R.J., 2015. CD4(+) T-
11 cells, gammadelta T-cells and B-cells are associated with lack of vaccine protection
12 in *Mycobacterium avium* subspecies *paratuberculosis* infection. Vaccine 33, 149-
13 155.

14 Delgado, L., Marín, J.F., Muñoz, M., Benavides, J., Juste, R.A., García-Pariente, C.,
15 Fuertes, M., González, J., Ferreras, M.C., Pérez, V., 2013. Pathological findings in
16 young and adult sheep following experimental infection with 2 different doses of
17 *Mycobacterium avium* subspecies *paratuberculosis*. Vet. Pathol. 50, 857-866.

18 Dennis, M. M., Reddacliff, L.A., Whittington, R.J., 2011. Longitudinal study of
19 clinicopathological features of Johne's disease in sheep naturally exposed to
20 *Mycobacterium avium* subspecies *paratuberculosis*. Vet. Pathol. 48, 565-575.

21 Derakhshani, H., De Buck, J., Mortier, R., Barkema, H.W., Krause, D.O., Khafipour, E.,
22 2015. The features of fecal and ileal mucosa-associated microbiota in dairy calves

1 during early infection with *Mycobacterium avium* subspecies *paratuberculosis*.
2 Front. Microbiol. 7, 426.

3 De Silva, K., Plain, K.M., Begg, D.J., Purdie, A.C., Whittington R.J., 2015. CD4(+) T-
4 cells, gammadelta T-cells and B-cells are associated with lack of vaccine protection
5 in *Mycobacterium avium* subspecies *paratuberculosis* infection. Vaccine 33, 149-
6 155.

7 Deutz, A., Spengler, J., Wagner, P., Rosengarten, R., Köfer, J., 2005. *Mycobacterium*
8 *avium* subsp. *paratuberculosis* in wild animal species and cattle in Styria/Austria.
9 Berl. Munch. Tierarztl. Wochenschr. 118, 314-320.

10 De Val, B.P., Nofrarias, M., Lopez-Soria, S., Garrido, J.M., Vordermeier, H.M.,
11 Villarreal-Ramos, B., Martín, M., Puentes, E., Juste, R.A., Domingo, M., 2012.
12 Effects of vaccination against paratuberculosis on tuberculosis in goats: diagnostic
13 interferences and cross-protection. BMC Vet. Res. 8, 191.

14 Devonshire, A.S., O'Sullivan, D.M., Honeyborne, I., Jones, G., Karczmarczyk, M.,
15 Pavšič, J., Gutteridge, A., Milavec, M., Mendoza, P., Schimmel, H., Van
16 Heuverswyn, F., Gorton, R., Cirillo, D.M., Borroni, E., Harris, K., Barnard, M.,
17 Heydenrych, A., Ndusilo, N., Wallis, C.L., Pillay, K., Barry, T., Reddington, K.,
18 Richter, E., Mozioğlu, E., Akyürek, S., Yalçınkaya, B., Akgoz, M., Žel, J., Foy,
19 C.A., McHugh, T.D., Huggett, J.F., 2016. The use of digital PCR to improve the
20 application of quantitative molecular diagnostic methods for tuberculosis. BMC
21 Infect. Dis. 16, 366.

1 Dhand, N.K., Eppleston, J., Whittington, R.J., Windsor, P.A., 2016. Changes in
2 prevalence of ovine paratuberculosis following vaccination with Gudair: Results of
3 a longitudinal study conducted over a decade. *Vaccine* 34, 5107–5113.

4 Dobson, B., Liggett, S., O'Brien, R., Griffin, J.F., 2013. Innate immune markers that
5 distinguish red deer (*Cervus elaphus*) selected for resistant or susceptible genotypes
6 for Johne's disease. *Vet. Res.* 44, 5.

7 Dorshorst, N.C., Collins, M.T., Lombard, J.E., 2006. Decision analysis model for
8 paratuberculosis control in commercial dairy herds. *Prev. Vet. Med.* 75, 92-122.

9 Eisenberg, S.W., Koets, A.P., Hoeboer, J., Bouman, M., Heederik, D., Nielen, M., 2010a.
10 Presence of *Mycobacterium avium* subsp. *paratuberculosis* in environmental
11 samples collected on commercial Dutch dairy farms. *Appl. Environ. Microbiol.*
12 76, 6310-6312.

13 Eisenberg, S.W., Nielen, M., Santema, W., Houwers, D.J., Heederik, D., Koets A.P.,
14 2010b. Detection of spatial and temporal spread of *Mycobacterium avium* subsp.
15 *paratuberculosis* in the environment of a cattle farm through bio-aerosols. *Vet.*
16 *Microbiol.* 143, 284-292.

17 Eisenberg, S.W., Koets, A.P., Nielen, M., Heederik, D., Mortier, R., De Buck, J., Orsel,
18 K., 2011. Intestinal infection following aerosol challenge of calves with
19 *Mycobacterium avium* subspecies *paratuberculosis*. *Vet. Res.* 42, 117.

20 Eisenberg, S.W., Rutten, V.P., Koets, A.P., 2015^a. Dam *Mycobacterium avium* subspecies
21 *paratuberculosis* (MAP) infection status does not predetermine calves for future
22 shedding when raised in a contaminated environment: a cohort study. *Vet. Res.* 46,
23 70.

1 Eisenberg, S.W.F., Veldman, E., Rutten, V.P.M.G., Koets, A.P., 2015b. A longitudinal
2 study of factors influencing the results of a *Mycobacterium avium* ssp.
3 *paratuberculosis* antibody ELISA in milk of dairy cows. J. Dairy Sci. 98, 2345-
4 2355.

5 Elliott, N.G., Hough, R.L., Avery, L.M., Maltin, C.A., Campbell, C.D., 2015.
6 Environmental risk factors in the incidence of Johne's disease. Crit. Rev. Microbiol.
7 41, 488-507.

8 Ellis-Iversen, J., Cook, A.J., Watson, E., Nielen, M., Larkin, L., Wooldridge, M.,
9 Hogeveen, H., 2010. Perceptions, circumstances and motivators that influence
10 implementation of zoonotic control programs on cattle farms. Prev. Vet. Med. 93,
11 276-285.

12 Eltholth, M.M., Marsh, V.R., Van Winden, S., Guitian, F.J., 2009. Contamination of food
13 products with *Mycobacterium avium paratuberculosis*: a systematic review. J.
14 Appl. Microbiol. 107, 1061-1071.

15 Facciuolo, A., Mutharia, L.M., 2014. Mycobacterial glycoproteins: a novel subset of
16 vaccine candidates. Front. Cell Infect. Microbiol. 4, 133.

17 Facciuolo, A., Kelton, D.F., Mutharia, L.M., 2013. Novel secreted antigens of
18 *Mycobacterium paratuberculosis* as serodiagnostic biomarkers for Johne's disease
19 in cattle. Clin. Vaccine Immunol. 20, 1783-1791

20 Faisal, S.M., Chen, J.W., Yan, F., Chen, T.T., Useh, N.M., Yan, W., Guo, S., Wang, S.J.,
21 Glaser, A.L., McDonough, S.P., Singh, B., Davis, W.C., Akey, B.L., Chang, Y.F.,
22 2013. Evaluation of a *Mycobacterium avium* subsp. *paratuberculosis* leuD mutant
23 as a vaccine candidate against challenge in a caprine model. Clin. Vaccine

1 Immunol. 20, 572-581.

2 Fecteau, M.E., Whitlock, R.H., Buergelt, C.D., Sweeney, R.W., 2010. Exposure of young
3 dairy cattle to *Mycobacterium avium* subsp. *paratuberculosis* (MAP) through
4 intensive grazing of contaminated pastures in a herd positive for Johne's disease.
5 Can. Vet. J. 51, 198-200.

6 Feller, M., Huwiler, K., Stephan, R., Altpeter, E., Shang, A., Furrer, H., Pfyffer, G.E.,
7 Jemmi, T., Baumgartner, A., Egger, M., 2007. *Mycobacterium avium* subspecies
8 *paratuberculosis* and Crohn's disease: a systematic review and meta-analysis.
9 Lancet Infect. Dis. 7, 607-613.

10 Ferroglio, E., Nebbia, P., Robino, P., Rossi, L., Rosati, S., 2000. *Mycobacterium*
11 *paratuberculosis* infection in two free-ranging Alpine ibex. Rev. Sci. Tech. 19,
12 859-862.

13 Fisher, C.A., Bhattarai, E.K., Osterstock, J.B., Dowd, S.E., Seabury, P.M., Vikram, M.,
14 Whitlock, R.H., Schukken, Y.H., Schnabel, R.D., Taylor, J.F., Womack, J.E.,
15 Seabury, C.M., 2011. Evolution of the bovine TLR gene family and member
16 associations with *Mycobacterium avium* subspecies *paratuberculosis* infection.
17 PloS One 6, e27744.

18 Fock-Chow-Tho, D., Topp, E., Ibeagha-Awemu, E.A., Bissonnette, N., 2017.
19 Comparison of commercial DNA extraction kits and quantitative PCR systems for
20 better sensitivity in detecting the causative agent of paratuberculosis in dairy cow
21 fecal samples. J. Dairy Sci. 100, 572-581.

22 Fritsch, I., Luyven, G., Köhler, H., Lutz, W., Möbius, P., 2012. Suspicion of
23 *Mycobacterium avium* subsp. *paratuberculosis* transmission between cattle and

1 wild-living red deer (*Cervus elaphus*) by multitarget genotyping. Appl. Environ.
2 Microbiol. 78, 1132–1139.

3 Frössling, J., Wahlström, H., Agren, E.C., Cameron, A., Lindberg, A., Sternberg
4 Lewerin, S., 2013. Surveillance system sensitivities and probability of freedom
5 from *Mycobacterium avium* subsp. *paratuberculosis* infection in Swedish cattle.
6 Prev. Vet. Med. 108, 47-62.

7 Garcia, A.B., Shalloo, L., 2015. Invited review: The economic impact and control of
8 paratuberculosis in cattle. J. Dairy Sci., 98, 5019-5039.

9 Garforth, C., 2015. Livestock keepers' reasons for doing and not doing things which
10 governments, vets and scientists would like them to do. Zoonoses Public Health. 62
11 Suppl 1, 29-38.

12 Geraghty, T., Graham, D.A., Mullowney, P., More, S.J., 2014. A review of bovine
13 Johne's disease control activities in 6 endemically infected countries. Prev. Vet.
14 Med. 116, 1-11.

15 Ghosh, P., Shippy, D.C., Talaat, A.M., 2015. Superior protection elicited by live-
16 attenuated vaccines in the murine model of paratuberculosis. Vaccine 33, 7262-
17 7270.

18 Gollnick, N.S., Mitchell, R.M., Baumgart, M., Janagama, H.K., Sreevatsan, S., Schukken,
19 Y.H., 2007. Survival of *Mycobacterium avium* subsp. *paratuberculosis* in bovine
20 monocyte-derived macrophages is not affected by host infection status but
21 depends on the infecting bacterial genotype. Vet. Immunol. Immunopathol. 120,
22 93–105.

23 Gonda, M.G., Chang, Y.M., Shook, G.E., Collins, M.T., Kirkpatrick, B.W., 2006.

1 Genetic variation of *Mycobacterium avium* ssp. *paratuberculosis* infection in US
2 Holsteins. J. Dairy Sci. 89, 1804-1812.

3 Griebel, P., Arsenault, R., Facciolo, A., Kusalik, A., Liang, G., Määttä, P., Mutharia,
4 L., Trost, B., Napper, S., Luo Guan, L., 2014. Models and methods to dissect
5 mucosal immune responses following MAP infection. In: Proc. 12th Int. Colloq.
6 Paratuberculosis 4–6.

7 Groenendaal, H., Nielen, M., Jalvingh, A.W., Horst, S.H., Galligan, D.T., Hesselink,
8 J.W., 2002. A simulation of Johne's disease control. Prev. Vet. Med. 54, 225-245.

9 Groenendaal, H., Nielen, M., Hesselink, J.W., 2003. Development of the Dutch Johne's
10 disease control program supported by a simulation model. Prev. Vet. Med. 60, 69-
11 90.

12 Groenendaal, H., Zagmutt, F.J., Patton, E.A., Wells, S.J., 2015. Cost-benefit analysis of
13 vaccination against *Mycobacterium avium* ssp. *paratuberculosis* in dairy cattle,
14 given its cross-reactivity with tuberculosis tests. J. Dairy Sci. 98, 6070-6084.

15 Gurung, R.B., Begg, D.J., Purdie, A.C., Whittington, R.J., 2013. Antigenicity in sheep of
16 synthetic peptides derived from stress-regulated *Mycobacterium avium* subsp.
17 *paratuberculosis* proteins and comparison with recombinant protein and complex
18 native antigens. Vet. Immunol. Immunopathol. 158, 46-52.

19 Heffernan, C., Nielsen, L., Thomson, K., Gunn, G., 2008. An exploration of the drivers to
20 bio-security collective action among a sample of UK cattle and sheep farmers. Prev.
21 Vet. Med. 87, 358-372.

1 Heuer, C., Mitchell, R.M., Schukken, Y.H., Lu, Z., Verdugo, C., Wilson, P.R., 2012.
2 Modelling transmission dynamics of paratuberculosis of red deer under pastoral
3 farming conditions. *Prev. Vet. Med.* 106, 63-74.

4 Hines, M.E. 2nd, Stabel, J.R., Sweeney, R.W., Griffin, F., Talaat, A.M., Bakker, D.,
5 Benedictus, G., Davis, W.C., de Lisle, G.W., Gardner, I.A. Juste, R.A., Kapur, V.,
6 Koets, A., McNair, J., Pruitt, G., Whitlock, R.H., 2007. Experimental challenge
7 models for Johne's disease: a review and proposed international guidelines. *Vet.*
8 *Microbiol.* 122, 197-222.

9 Hines, M.E. 2nd, Turnquist, S.E., Ilha, M.R., Rajeev, S., Jones, A.L., Whittington, L.,
10 Bannantine, J.P., Barletta, R.G., Gröhn, Y.T., Katani, R., Talaat, A.M., Li, L.,
11 Kapur, V., 2014. Evaluation of novel oral vaccine candidates and validation of a
12 caprine model of Johne's disease. *Front. Cell. Infect. Microbiol.* 4, 26.

13 Hinger, M., Brandt, H., Horner, S., Erhardt, G., 2007. Short communication: Association
14 analysis of microsatellites and *Mycobacterium avium* subspecies *paratuberculosis*
15 antibody response in German Holsteins. *J. Dairy Sci.* 90, 1957-1961.

16 Hoek, A., Rutten, V.P., van der Zee, R., Davies, C.J., Koets, A.P., 2010. Epitopes of
17 *Mycobacterium avium* ssp. *paratuberculosis* 70kDa heat-shock protein activate
18 bovine helper T cells in outbred cattle. *Vaccine* 28, 5910-5919.

19 Hutchings, M.R., Sevenson, K., Greig, A., Davidson, R.S., Marion, G., Judge, J., 2010.
20 Infection of non-ruminant wildlife by *Mycobacterium avium* subsp.
21 *paratuberculosis*. In: Behr, M.A., Collins, D.M. (Eds.), *Paratuberculosis:*
22 *organism, disease, control*. CABI. ISBN 9781845936136, pp. 188-200.

1 Huygen, K., 2014. The immunodominant T-cell epitopes of the mycolyl-transferases of
2 the antigen 85 complex of *M. tuberculosis*. Front. Immunol. 5, 321.

3 Janagama, H.K., Jeong, Ki., Kapur, V., Coussens, P., Sreevatsan, S., 2006. Cytokine
4 responses of bovine macrophages to diverse clinical *Mycobacterium avium*
5 subspecies *paratuberculosis* strains. BMC Microbiol. 6, 10.

6 Jansen, J., Lam, T.J.G.M., 2012. The role of communication in improving udder health.
7 Vet. Clin. North Am. Food Anim. Pract. 28, 363-379.

8 Jansen, J., van Schaik, G., Renes, R.J., Lam, T.J., 2010. The effect of a national mastitis
9 control program on the attitudes, knowledge, and behavior of farmers in the
10 Netherlands. J. Dairy Sci. 93, 5737-5747.

11 Jayarao, B.M., Pillai, S.R., Wolfgang, D.R., Griswolf, D.R., Rossiter, C.A., Tewari, D.,
12 Burns, C.M., Hutchinson, L.J., 2004. Evaluation of IS900 PCR assay for detection
13 of *Mycobacterium avium* subspecies *paratuberculosis* infection in cattle using
14 quarter milk and bulk milk samples. Foodborne Pathog. Dis. 1, 17-26.

15 Johnston, C.D., Bannantine, J.P., Govender, R., Endersen, L., Pletzer, D., Weingart, H.,
16 Coffey, A., O'Mahony, J., Sleator, R.D., 2014. Enhanced expression of codon
17 optimized *Mycobacterium avium* subsp. *paratuberculosis* antigens in
18 *Lactobacillus salivarius*. Front. Cell. Infect. Microbiol. 4, 120.

19 Kalis, C.H.J., Hesselink, J.W., Barkema, H.W., Collins, M.T., 2001. Use of long-term
20 vaccination with a killed vaccine to prevent fecal shedding of *Mycobacterium*
21 *avium* subsp *paratuberculosis* in dairy herds. Am. J. Vet. Res. 62, 270-274.

22 Kalis, C.H.J., Barkema, H.W., Hesselink, J.W., Van Maanen, C., Collins, M.T., 2002.
23 Evaluation of two absorbed ELISAs and a Complement Fixation Test as

1 replacements for fecal culture in the detection of cows shedding *Mycobacterium*
2 *avium* subspecies *paratuberculosis*. J. Vet. Diagn. Invest. 14, 219-224.

3 Kalis, C.H.J., Collins, M.T., Hesselink, J.W., Barkema, H.W., 2003. Specificity of two
4 tests for the early diagnosis of bovine paratuberculosis based on cell-mediated
5 immunity: the Johnin skin test and the gamma interferon assay. Vet. Microbiol. 97,
6 73-86.

7 Kalis, C.H.J., Collins, M.T., Barkema, H.W., Hesselink, J.W., 2004. Certification of
8 herds as free of *Mycobacterium paratuberculosis* infection: actual pooled faecal
9 results versus certification model predictions. Prev. Vet. Med. 65, 189-204.

10 Kasnitz, N., Köhler, H., Weigoldt, M., Gerlach, G.F., Möbius, P., 2013. Stability of
11 genotyping target sequences of *Mycobacterium avium* subsp. *paratuberculosis*
12 upon cultivation on different media, in vitro- and in vivo passage, and natural
13 infection. Vet. Microbiol. 167, 573–583.

14 Kathaperumal, K., Park, S.U., McDonough, S., Stehman, S., Akey, B., Huntley, J.,
15 Wong, S., Chang, C.F., Chang, Y.F., 2008. Vaccination with recombinant
16 *Mycobacterium avium* subsp. *paratuberculosis* proteins induces differential
17 immune responses and protects calves against infection by oral challenge.
18 Vaccine 26, 1652-1663.

19 Kathaperumal, K., Kumanan, V., McDonough, S., Chen, L.H., Park, S.U., Moreira, M.A.,
20 Akey, B., Huntley, J., Chang, C.F., Chang, Y.F., 2009. Evaluation of immune
21 responses and protective efficacy in a goat model following immunization with a
22 cocktail of recombinant antigens and a polyprotein of *Mycobacterium avium* subsp.
23 *paratuberculosis*. Vaccine 27, 123-135.

1 Kawaji, S., Taylor, D.L., Mori, Y., Whittington, R.J., 2007. Detection of *Mycobacterium*
2 *avium* subsp. *paratuberculosis* in ovine faeces by direct quantitative PCR has
3 similar or greater sensitivity compared to radiometric culture. Vet. Microbiol.
4 125, 36-48.

5 Kelton, D., Van De Water, D., Cantin, R., Hand, K., Innes, C., Todd, C., 2014. A
6 potential role for bulk milk or herd pool ELISA testing in a Johne's disease
7 control program. Proc. 12 Intern. Colloq. Paratuberculosis, pp 71.

8 Kennedy, D.J., 2001. Control of paratuberculosis. Bull. Int. Dairy Fed. 364, 29-45.

9 Kennedy, D.J., 2011. International efforts at paratuberculosis control. Vet. Clin. North
10 Am. Food Anim. Pract. 27, 647-654.

11 Khare, S., Ficht, T.A., Santos, R.L., Romano, J., Ficht, A.R., Zhang, S., Grant, I.R.,
12 Libal, M., Hunter, D., Adams, L.G., 2004. Rapid and sensitive detection of
13 *Mycobacterium avium* subsp. *paratuberculosis* in bovine milk and feces by a
14 combination of immunomagnetic bead separation-conventional PCR and real-time
15 PCR. J. Clin. Microbiol. 42, 1075-1081.

16 Khol, J.L., Wassertheurer, M., Sodoma, E., Revilla-Fernandey, S., Damoser, J.,
17 Österreicher, E., Dünser, M., Kleb, U., Baumgartner, W., 2013. Long-term
18 detection of *Mycobacterium avium* subspecies *paratuberculosis* in individual and
19 bulk tank milk from a dairy herd with a low prevalence of Johne's disease. J. Dairy
20 Sci. 96, 3517-3524.

21 Kiehnbaum, L.A., Amonsin, A., Wells, S.J., Kapur, V., 2005. Amplified fragment length
22 polymorphism to detect clonal diversity and distribution of *Mycobacterium avium*

1 subspecies *paratuberculosis* in selected Minnesota dairy cattle. J. Vet. Diagn.
2 Invest. 17, 311-315.

3 Kingham, L., Links, I., 2012. Development of a group approach to facilitative vaccination
4 for ovine Johne's disease (OJD) in New South Wales. Page 178 in 11th
5 International Colloquium on Paratuberculosis Proc. Sydney, Australia

6 Kirkeby, C., Græsbøll, K., Halasa, T., Toft, N., Nielsen, S.S., 2015. Mean effective
7 sensitivity for *Mycobacterium avium* subsp. *paratuberculosis* infection in cattle
8 herds. BMC Vet. Res. 11, 190.

9 Kirkpatrick, B.W., Shook, G.E., 2011. Genetic susceptibility to paratuberculosis. Vet.
10 Clin. North Am. Food Am. Pract. 27, 559-571.

11 Klawonn, W., Einax, E., Pützschel, R., Schmidt, M., Donat, K., 2016. Johne's disease:
12 reliability of environmental sampling to characterize *Mycobacterium avium*
13 subspecies *paratuberculosis* (MAP) infection in beef cow-calf herds. Epidemiol.
14 Infect. 144, 2392-2400.

15 Kluge, J.P., Merkal, R.S., Monlux, W.S., Larsen, A.B., Kopecky, K.E., Ramsey, F.K.,
16 Lehmann, R.P., 1968. Experimental paratuberculosis in sheep after oral,
17 intratracheal, or intravenous inoculation lesions and demonstration of etiologic
18 agent. Am. J. Vet. Res. 29, 953-962.

19 Koets, A.P., Adugna, G., Janss, L.L., van Weering, H.J., Kalis, C.H., Wentink, G.H.,
20 Rutten, V.P., Schukken, Y.H., 2000. Genetic variation of susceptibility to
21 *Mycobacterium avium* subsp. *paratuberculosis* infection in dairy cattle. J. Dairy
22 Sci. 83, 2702-2708.

1 Koets, A., Hoek, A., Langelaar, M., Overdijk, M., Santema, W., Franken, P., van Eden,
2 W., Rutten, V., 2006. Mycobacterial 70 kD heat-shock protein is an effective
3 subunit vaccine against bovine paratuberculosis. *Vaccine* 24, 2550-2559.

4 Kormendy, B., 1992. Paratuberculosis vaccine in a large dairy herd. *Acta Vet. Hung.* 40,
5 171-184.

6 Kovich, D.A., Wells, S.J., Friendshuh, K., 2006. Evaluation of the Voluntary Johne's
7 Disease Herd Status Program as a source of replacement cattle. *J. Dairy Sci.* 89,
8 3466-3470.

9 Kralik, P., Beran, V., Pavlik, I., 2012. Enumeration of *Mycobacterium avium* subsp.
10 *paratuberculosis* by quantitative real-time PCR, culture on solid media and
11 optical densitometry. *BMC Res. Notes.* 5, 114.

12 Kudahl, A.B., Nielsen, S.S., Ostergaard, S., 2011. Strategies for time of culling in control
13 of paratuberculosis in dairy herds. *J. Dairy Sci.* 94, 3824-3834.

14 Kupper, J., Brandt, H., Donat, K., Erhardt, G., 2012. Heritability estimates for
15 *Mycobacterium avium* subspecies *paratuberculosis* status of German Holstein
16 cows tested by fecal culture. *J. Dairy Sci.* 95, 2734-2739.

17 Kurade, N.P., Tripathi, B.N., Rajukumar, K., 2004. Sequential development of histologic
18 lesions and their relationship with bacterial isolation, fecal shedding, and immune
19 responses during progressive stages of experimental infection of lambs
20 with *Mycobacterium avium* subsp. *paratuberculosis*. *Vet. Pathol.* 41, 378-387.

21 Laurin, E.L., Chaffer, M., McClure, J.T., McKenna, S.L., Keefe, G.P., 2015. The
22 association of detection method, season, and lactation stage on identification of

1 fecal shedding in *Mycobacterium avium* ssp. *paratuberculosis* infectious dairy
2 cows. J. Dairy Sci. 98, 211-220.

3 Lavers, C., Barkema, H.W., Dohoo, I.R., McKenna, S.L.B., Keefe, G.P., 2014.
4 Evaluation of milk ELISA for detection of *Mycobacterium avium* subspecies
5 *paratuberculosis* in dairy herds and association with within-herd prevalence. J.
6 Dairy Sci. 97, 299-309.

7 Leite, F.L., Reinhardt, T.A., Bannantine, J.P., Stabel, J.R., 2015. Envelope protein
8 complexes of *Mycobacterium avium* subsp. *paratuberculosis* and their
9 antigenicity. Vet. Microbiol. 175, 275-285.

10 Lu, Z., Mitchell, R.M., Smith, R.L., Van Kessel, J.S., Chapagain, P.P., Schukken, Y.H.,
11 Gröhn, Y.T., 2008. The importance of culling in Johne's disease control. J. Theor.
12 Biol. 254, 135-146.

13 Lugton, I.W., 2004. Review of possible links between the clinical expression of
14 paratuberculosis and deficiency of macro and micronutrients. Aust. Vet. J. 82,
15 490-496.

16 Lund, B.M., Gould, G.W., Rampling, A.M., 2002. Pasteurization of milk and the heat
17 resistance of *Mycobacterium avium* subsp. *paratuberculosis*: a critical review of
18 the data. Intern. J. Food Microbiol. 77, 135-145.

19 Lybeck, K.R., Storset, A.K., Djønnø, B., Valheim, M., Olsen, I., 2011. Faecal shedding
20 detected earlier than immune responses in goats naturally infected with
21 *Mycobacterium avium* subsp. *paratuberculosis*. Res. Vet. Sci. 91, 32-39.

1 Machackova, M., Svastova, P., Lamka, J., Parmova, I., Liska, V., Smolik, J., Fischer,
2 O.A., Pavlik, I., 2004. Paratuberculosis in farmed and free-living wild ruminants
3 in the Czech Republic (1999-2001). Vet. Microbiol. 101, 225-234.

4 Mackintosh, C.G., Griffin, J.F., 2010. Paratuberculosis in deer, camelids and other
5 ruminants. In: Behr, M.A., Collins, D.M. (Eds.), Paratuberculosis: organism,
6 disease, control. CABI. ISBN 9781845936136, pp. 179-187.

7 Marcé, C., Ezanno, P., Weber, M.F., Seegers, H., Pfeiffer, D.U., Fourichon, C., 2010.
8 Invited review: modeling within-herd transmission of *Mycobacterium avium*
9 subspecies *paratuberculosis* in dairy cattle: a review. J. Dairy Sci. 93, 4455-4470.

10 Marcé, C., Ezanno, P., Seegers, H., Pfeiffer, D.U., Fourichon, C., 2011. Within-herd
11 contact structure and transmission of *Mycobacterium avium* subspecies
12 *paratuberculosis* in a persistently infected dairy cattle herd. Prev. Vet. Med. 100,
13 116-125.

14 McAloon, C.G., Doherty, M.L., Whyte, P., O'Grady, L., More, S.J., Messam, L.L., Good,
15 M., Mullooney, P., Strain, S., Green, M.J., 2016. Bayesian estimation of
16 prevalence of paratuberculosis in dairy herds enrolled in a voluntary Johne's
17 Disease Control Programme in Ireland. Prev. Vet. Med. 128, 95-100.

18 McGregor, H., Dhand, N.K., Dhungyel, O.P., Whittington, R.J., 2012. Transmission of
19 *Mycobacterium avium* subsp. *paratuberculosis*: Dose-response and age-based
20 susceptibility in a sheep model. Prev. Vet. Med. 107, 76-84.

21 McKenna, S.L.B., Keefe, G.P., Barkema, H.W., Sockett, D.C., 2005a. Evaluation of three
22 ELISAs for *Mycobacterium avium* subsp. *paratuberculosis* using tissue and fecal
23 culture as comparison standards. Vet. Microbiol. 110, 105-111.

1 McKenna, S.L.B., Sockett, D.C., Keefe, G.P., McClure, J., VanLeeuwen, J.A., Barkema,
2 H.W., 2005b. Comparison of two enzyme-linked immunosorbent assays for
3 diagnosis of *Mycobacterium avium* subsp. *paratuberculosis*. J. Vet. Diagn. Invest.
4 17, 463-466.

5 McKenna, S.L.B., Vanleeuwen, J.A., Barkema, H.W., Jansen, J.T., Hauer, G., Hendrick,
6 S.H., Cote, G., Salsberg, E.B., Empringham, R.E., 2006a. Proposed Canadian
7 voluntary national Johne's Disease prevention and control program. Can. Vet. J. 47,
8 539-541.

9 McKenna, S.L., Keefe, G.P., Tiwari, A., VanLeeuwen, J., Barkema, H.W., 2006b.
10 Johne's disease in Canada part II: disease impacts, risk factors, and control
11 programs for dairy producers. Can. Vet. J. 2006c, 47, 1089-1099.

12 Mikkelsen, H., Aagaard, C., Nielsen, S.S., Jungersen, G., 2012. Correlation of antigen-
13 specific IFN- γ responses of fresh blood samples from *Mycobacterium avium* subsp.
14 *paratuberculosis* infected heifers with responses of day-old samples co-cultured
15 with IL-12 or anti-IL-10 antibodies. Vet. Immunol. Immunopathol. 147, 69-76.

16 Minozzi, G., Williams, J.L., Stella, A., Strozzi, F., Luini, M., Settles, M.L., Taylor, J.F.,
17 Whitlock, R.H., Zanella, R., Neibergs, H.L., 2012. Meta-analysis of two genome-
18 wide association studies of bovine paratuberculosis. PloS One 7, e32578.

19 Mita, A., Mori, Y., Nakagawa, T., Tasaki, T., Utiyama, K., Mori, H., 2016. Comparison
20 of fecal pooling methods and DNA extraction kits for the detection of
21 *Mycobacterium avium* subspecies *paratuberculosis*. Microbiologyopen 5, 134-142.

22 Mitchell, R.M., Schukken, Y., Koets, A., Weber, M., Bakker, D., Stabel, J., Whitlock,
23 R.H., Louzoun, Y., 2015. Differences in intermittent and continuous fecal shedding

1 patterns between natural and experimental *Mycobacterium avium* subspecies
2 *paratuberculosis* infections in cattle. Vet. Res. 46, 66.

3 Mortier, R.A.R., Barkema, H.W., Bystrom, J.M., Illanes, O., Orsel, K., Wolf, R., Atkins,
4 G., De Buck, J., 2013. Evaluation of age-dependent susceptibility in calves infected
5 with two doses of *Mycobacterium avium* subspecies *paratuberculosis* using
6 pathology and tissue culture. Vet. Res. 44, 94.

7 Mortier, R.A.R., Barkema, H.W., Wilson, T.A., Sajobi, T.T., Wolf, R., De Buck, J.,
8 2014a. Dose-dependent interferon-gamma release in dairy calves experimentally
9 infected with *Mycobacterium avium* subspecies *paratuberculosis*. Vet. Immunol.
10 Immunopathol. 161, 205-210.

11 Mortier, R.A.R., Barkema, H.W., Orsel, K., Wolf, R., Negron, M.E., Atkins, G.A., De
12 Buck, J. 2014b. Antibody response early after experimental infection with
13 *Mycobacterium avium* subspecies *paratuberculosis* in dairy calves. J. Dairy Sci. 97,
14 5558-5565.

15 Mortier, R.A.R., Barkema, H.W., Orsel, K., Wolf, R., De Buck, J., 2014c. Shedding
16 patterns of dairy calves experimentally infected with *Mycobacterium avium*
17 subspecies *paratuberculosis*. Vet. Res. 45, 71.

18 Mortier, R.A.R., Barkema, H.W., Orsel, K., Muench, G.P., Bystrom, J., De Buck, J.,
19 2015a. Longitudinal evaluation of diagnostics in experimentally infected young
20 calves during subclinical and clinical paratuberculosis. Can. Vet. J., 56, 1266-1270.

21 Mortier, R.A.R., Barkema, H.W., De Buck, J., 2015b. Susceptibility to and diagnosis of
22 *Mycobacterium avium* subspecies *paratuberculosis* infection in dairy calves: A
23 review. Prev. Vet. Med. 121, 189-198.

1 Motiwala, A.S., Strother, M., Amonsin, A., Byrum, B., Naser, S.A., Stabel, J.R., Shulaw,
2 W.P., Bannantine, J.P., Kapur, V., Sreevatsan, S., 2003. Molecular epidemiology
3 of *Mycobacterium avium* subsp. *paratuberculosis*: evidence for limited strain
4 diversity, strain sharing, and identification of unique targets for diagnosis. J. Clin.
5 Microbiol. 41, 2015–2026.

6 Motiwala, A.S., Amonsin, A., Strother, M., Manning, E.J., Kapur, V., Sreevatsan, S., 2004.
7 Molecular epidemiology of *Mycobacterium avium* subsp. *paratuberculosis* isolates
8 recovered from wild animal species. J. Clin. Microbiol. 42, 1703-1712.

9 Motiwala, A.S., Janagama, H.K., Paustian, M.L., Zhu, X., Bannantine, J.P., Kapur, V.,
10 Sreevatsan, S., 2006. Comparative transcriptional analysis of human macrophages
11 exposed to animal and human isolates of *Mycobacterium avium* subspecies
12 *paratuberculosis* with diverse genotypes. Infect. Immun. 74, 6046–6056.

13 Muskens, J., van Zijderveld, F., Eger, A., Bakker, D., 2002. Evaluation of the long-term
14 immune response in cattle after vaccination against paratuberculosis in two Dutch
15 dairy herds. Vet. Microbiol. 86, 269-278

16 Nagel-Alne, G.E., Asheim, L.J., Hardaker, J.B., Sølverød, L., Lindheim, D., Valle, P.S.,
17 2014. The Norwegian Healthier Goats programme--a financial cost-benefit
18 analysis. Prev. Vet. Med. 114, 96-105.

19 Nielsen, S.S., 2008. Transitions in diagnostic tests used for detection of *Mycobacterium*
20 *avium* subsp. *paratuberculosis* infections in cattle. Vet. Microbiol. 132, 274-282.

21 Nielsen, S.S., 2011. Dairy farmers' reasons for participation in the Danish control
22 programme on bovine paratuberculosis. Prev. Vet. Med. 98, 279-283.

1 Nielsen, S.S., Toft, N., 2008. Ante mortem diagnosis of paratuberculosis: a review of
2 accuracies of ELISA, interferon-gamma assay and faecal culture techniques. Vet.
3 Microbiol. 129, 217-235.

4 Nielsen, S.S., Toft, N., 2011. Effect of management practices on paratuberculosis
5 prevalence in Danish dairy herds. J. Dairy Sci. 94, 1849-1857.

6 Nielsen, S.S., Toft, N., 2014. Bulk tank milk ELISA for detection of antibodies to
7 *Mycobacterium avium* subsp. *paratuberculosis*: correlation between repeated tests
8 and within-herd antibody-prevalence. Prev. Vet. Med. 113, 96-102.

9 Nielsen, S.S., Jepsen, O.R., Aagaard, K., 2007. Control programme for paratuberculosis
10 in Denmark. Bull. Intern. Dairy Fed. 410/207: Proc. 1st ParaTB Forum, pp. 23-29.

11 Nielsen, S.S., Bjerre, H., Toft, N., 2008. Colostrum and milk as risk factors for infection
12 with *Mycobacterium avium* subspecies *paratuberculosis* in dairy cattle. J. Dairy
13 Sci. 91, 4610-4615.

14 Norton, S., Heuer, C., Jackson, R., 2009. A questionnaire-based cross-sectional study of
15 clinical Johne's disease on dairy farms in New Zealand. NZ Vet. J. 57, 34-43.

16 Oakey, J., Gavey, L., Singh, S.V., Platell, J., Waltisbuhl, D., 2014. Variable-number
17 tandem repeats genotyping used to aid and inform management strategies for a
18 bovine Johne's disease incursion in tropical and subtropical Australia. J. Vet.
19 Diagn. Invest. 26, 651-657.

20 OIE, 2012. Validation and certification of diagnostic assays. World Organisation for
21 Animal Health, Paris, France. Available at: [http://www.oie.int/en/our-scientific-](http://www.oie.int/en/our-scientific-expertise/registration-of-diagnostic-kits/background-information/)
22 [expertise/registration-of-diagnostic-kits/background-information/](http://www.oie.int/en/our-scientific-expertise/registration-of-diagnostic-kits/background-information/) (Accessed 9 May
23 2017).

1 Ott, S.L., Wells, S.J. Wagner, B.A., 1999. Herd-level economic losses associated with
2 Johne's disease on US dairy operations. *Prev. Vet. Med.* 40, 179-192.

3 Park, K.T., Allen, A.J., Bannantine, J.P., Seo, K.S., Hamilton, M.J., Abdellrazeq, G.S.,
4 Rihan, H.M., Grimm, A., Davis, W.C., 2011. Evaluation of two mutants of
5 *Mycobacterium avium* subsp. *paratuberculosis* as candidates for a live attenuated
6 vaccine for Johne's disease. *Vaccine* 29, 4709-4719.

7 Park, K.T., Allen, A.J., Barrington, G.M., Davis, W.C., 2014. Deletion of *relA* abrogates
8 the capacity of *Mycobacterium avium paratuberculosis* to establish an infection in
9 calves. *Front. Cell. Infect. Microbiol.* 4, 64.

10 Pearson, T., Okinaka, R.T., Foster, J.T., Keim, P., 2009. Phylogenetic understanding of
11 clonal populations in an era of whole genome sequencing. *Infect. Genet. Evol.* 9,
12 1010–1019.

13 Pillars, R.D., Grooms, D.L., Gardiner, D.C., Kaneene, J.B., 2011. Association between
14 risk-assessment scores and individual-cow Johne's disease-test status over time on
15 seven Michigan, USA dairy herds. *Prev. Vet. Med.* 98, 10-18.

16 Pinheiro, L.B., Coleman, V.A., Hindson, C.M., Herrmann, J., Hindson, B.J., Bhat, S.,
17 Emslie, K.R., 2012. Evaluation of a droplet digital polymerase chain reaction
18 format for DNA copy number quantification. *Anal. Chem.* 84, 1003-1011.

19 Plain, K.M., Begg, D.J., de Silva, K., Purdie, A.C., Whittington, R.J., 2012. Enhancement
20 of the interferon gamma assay to detect paratuberculosis using interleukin-7 and
21 interleukin-12 potentiation. *Vet. Immunol. Immunopathol.* 149, 28-37.

22 Plain, K.M., Marsh, I.B., Waldron, A.M., Galea, F., Whittington, A.M., Saunders, V.F.,
23 Begg, D.J., de Silva, K., Purdie, A.C., Whittington, R.J., 2014. High-throughput

1 direct fecal PCR assay for detection of *Mycobacterium avium* subsp.
2 *paratuberculosis* in sheep and cattle. J. Clin. Microbiol. 52, 745-757.

3 Pradhan, A.K., Mitchell, R.M., Kramer, A.J., Zurakowski, M.J., Fyock, T.L., Whitlock,
4 R.H., Smith, J.M., Hovingh, E., Van Kessel, J.A.S., Karns, J.S., Schukken, Y.H.,
5 2011. Molecular epidemiology of *Mycobacterium avium* subsp. *paratuberculosis* in
6 a longitudinal study of three dairy herds. J Clin Microbiol 49, 893–901.

7 Pritchard, T.C., Coffey, M.P., Bond, K.S., Hutchings, M.R., Wall, E., 2017. Phenotypic
8 effects of subclinical paratuberculosis (Johne's disease) in dairy cattle. J. Dairy Sci.
9 100, 679-690.

10 Pruvot, M., Forde, T.L., Steele, J., Kutz, S.J., De Buck, J., van der Meer, F., Orsel, K.,
11 2013. The modification and evaluation of an ELISA test for the surveillance of
12 *Mycobacterium avium* subsp. *paratuberculosis* infection in wild ruminants. BMC
13 Vet. Res. 9, 5.

14 Purdie, A.C., Plain, K.M., Begg, D.J., de Silva, K., Whittington, R.J., 2011. Candidate
15 gene and genome-wide association studies of *Mycobacterium avium* subsp.
16 *paratuberculosis* infection in cattle and sheep: a review. Comp. Immunol.
17 Microbiol. Infect. Dis. 34, 197-208.

18 Raizman, E.A., Fetrow, J.P., Wells, S.J., 2009. Loss of income from cows shedding
19 *Mycobacterium avium* subspecies *paratuberculosis* prior to calving compared with
20 cows not shedding the organism on two Minnesota dairy farms. J. Dairy Sci. 92,
21 4929-4936.

22 Rana, A., Rub, A., Akhter, Y., 2015. Proteome-wide B and T cell epitope repertoires in
23 outer membrane proteins of *Mycobacterium avium* subsp. *paratuberculosis* have

1 vaccine and diagnostic relevance: a holistic approach. J. Mol. Recognit. 28, 506-
2 520.

3 Rangel, S.J., Paré, J., Doré, E., Arango, J.C., Côté, G., Buczinski, S., Labrecque, O.,
4 Fairbrother, J.H., Roy, J.P., Wellemans, V., Fecteau, G., 2005. A systematic review
5 of risk factors associated with the introduction of *Mycobacterium avium* spp.
6 *paratuberculosis* (MAP) into dairy herds. Can. Vet. J. 56, 169-177.

7 Rathnaiah, G., Lamont, E.A., Harris, N.B., Fenton, R.J., Zinniel, D.K, Liu, X., Sotos, J.,
8 Feng, Z., Livneh-Kol, A., Shpigel, N.Y., Czuprynski, C.J., Sreevatsan, S., Barletta,
9 R.G., 2014. Generation and screening of a comprehensive *Mycobacterium avium*
10 subsp. *paratuberculosis* transposon mutant bank. Front. Cell. Infect. Microbiol. 4,
11 144.

12 Reddacliff, L., Eppleston, J., Windsor, P., Whittington, R., Jones, S., 2006. Efficacy of a
13 killed vaccine for the control of paratuberculosis in Australian sheep flocks. Vet.
14 Microbiol. 115, 77-90.

15 Ritter, C., Kwong, G.P., Wolf, R., Pickel, C., Slomp, M., Flaig, J., Mason, S., Adams,
16 C.L., Kelton, D.F., Jansen, J., De Buck, J., Barkema, H.W., 2015. Factors
17 associated with participation of Alberta dairy farmers in a voluntary,
18 management-based Johne's disease control program. J. Dairy Sci. 98, 7831-7845.

19 Ritter, C., Jansen, J., Roche, S., Kelton, D.F., Adams, C., Orsel, K., Erskine, R.J.,
20 Benedictus, G., Lam, T.J.G.M., Barkema, H.W, 2017. Invited review:
21 Determinants of farmers' adoption of management-based strategies for infectious
22 disease prevention and control. J. Dairy Sci. 100, 3329-3347.

1 Roche, S.M.R., 2014. Investigating the role of agricultural extension in influencing
2 Ontario dairy producer behaviour for Johne's disease control. PhD Thesis. Univ.
3 Guelph, Guelph, Ontario, Canada.

4 Roche, S.M., Jones-Bitton, A., Meehan, M., Von Massow, M., Kelton, D.F., 2015.
5 Evaluating the effect of Focus Farms on Ontario dairy producers' knowledge,
6 attitudes, and behavior toward control of Johne's disease. J. Dairy Sci. 98, 5222-
7 5240.

8 Romano, M., Huygen, K., 2009. DNA vaccines against mycobacterial diseases. Expert
9 Rev. Vaccines 8, 1237-1250.

10 Rosseels, V., Huygen, K., 2008. Vaccination against paratuberculosis. Expert Rev.
11 Vaccines 7, 817-832.

12 Rossiter, C.A., Burhans, W.S., 1996. Farm-specific approach to paratuberculosis (Johne's
13 disease) control. Vet. Clin. North Am., Food Anim. Pract. 12, 383-415.

14 Roupie, V., Viart, S., Leroy, B., Romano, M., Trinchero, N., Govaerts, M., Letesson, J.J.,
15 Wattiez, R., Huygen, K., 2012. Immunogenicity of eight *Mycobacterium avium*
16 subsp. *paratuberculosis* specific antigens in DNA vaccinated and Map infected
17 mice. Vet. Immunol. Immunopathol. 145, 74-85.

18 Roussel, A.J., Libal, M.C., Whitlock, R.L., Hairgrove, T.B., Barling, K.S., Thompson,
19 J.A., 2005. Prevalence of and risk factors for paratuberculosis in purebred beef
20 cattle. J. Am. Vet. Med. Assoc. 226, 773-778.

21 Russell, R.A., Bewley, J.M., 2011. Producer assessment of dairy extension programming
22 in Kentucky. J. Dairy Sci. 94, 2637-2647.

1 Santema, W.J., Hensen, S., Rutten, V.P., Koets, A.P., 2009. Heat shock protein 70
2 subunit vaccination against bovine paratuberculosis does not interfere with current
3 immunodiagnostic assays for bovine tuberculosis. *Vaccine* 27, 2312-2319.

4 Santema, W.J., Poot, J., Segers, R.P., Van den Hoff, D.J., Rutten, V.P., Koets, A.P.,
5 2012. Early infection dynamics after experimental challenge with *Mycobacterium*
6 *avium* subspecies *paratuberculosis* in calves reveal limited calf-to-calf
7 transmission and no impact of Hsp70 vaccination. *Vaccine* 30, 7032-7039.

8 Santema, W., Rutten, V., Segers, R., Poot, J., Hensen, S., Heesterbeek, H., Koets, A.,
9 2013. Postexposure subunit vaccination against chronic enteric mycobacterial
10 infection in a natural host. *Infect. Immun.* 81, 1990-1995.

11 Schillinger, S., Bridger, P.S., Bulun, H., Fischer, M., Akineden, O., Seeger, T., Barth, S.,
12 Henrich, M., Doll, K., Bülte, M., Menge, C., 2013. Flow cytometric detection of
13 *Mycobacterium avium* subsp. *paratuberculosis*-specific antibodies in
14 experimentally infected and naturally exposed calves. *Clin. Vaccine Immunol.* 20,
15 1457-1465.

16 Sergeant, E.S., Whittington, R.J., More, S.J., 2002. Sensitivity and specificity of pooled
17 faecal culture and serology as flock-screening tests for detection of ovine
18 paratuberculosis in Australia. *Prev. Vet. Med.* 52, 199-211.

19 Serraino, A., Arrigoni, N., Ostanello, F., Ricchi, M., Marchetti, G., Bonilauri, P.,
20 Bonfante, E., Giacometti, F., 2014. A screening sampling plan to detect
21 *Mycobacterium avium* subspecies *paratuberculosis*-positive dairy herds. *J. Dairy*
22 *Sci.* 97, 3344-3351.

1 Seth, M., Lamont, E.A., Janagama, H.K., Widdel, A., Vulchanova, L., Stabel, J.R.,
2 Waters, W.R., Palmer, M.V., Sreevatsan, S., 2009. Biomarker discovery in
3 subclinical mycobacterial infections of cattle. PloS ONE 4, e5478.

4 Settles, M., Zanella, R., McKay, S.D., Schnabel, R.D., Taylor, J.F., Whitlock, R.,
5 Schukken, Y., Van Kessel, J.S., Smith, J.M., Neibergs, H., 2009. A whole genome
6 association analysis identifies loci associated with *Mycobacterium avium* subsp.
7 *paratuberculosis* infection status in US Holstein cattle. Anim. Genet. 40, 655-662.

8 Settles, E.W., Kink, J.A., Talaat, A., 2014. Attenuated strains of *Mycobacterium avium*
9 subspecies *paratuberculosis* as vaccine candidates against Johne's disease.
10 Vaccine 32, 2062-2069.

11 Shaughnessy, R.G., Farrell, D., Riepema, K., Bakker, D., Gordon, S.V., 2015. Analysis
12 of biobanked serum from a *Mycobacterium avium* subsp *paratuberculosis* bovine
13 infection model confirms the remarkable stability of circulating miRNA profiles
14 and defines a bovine serum miRNA repertoire. PLoS One 10, e0145089.

15 Shin, M.K., Park, H.T., Shin, S.W., Jung, M., Im, Y.B., Park, H.E., Cho, Y.I., Yoo, H.S.,
16 2015. Whole-blood gene-expression profiles of cows infected with
17 *Mycobacterium avium* subsp. *paratuberculosis* reveal changes in immune
18 response and lipid metabolism. J. Microbiol. Biotechnol. 25, 255-267.

19 Shippy, D.C., Lemke, J.J., Berry, A., Nelson, K., Hines, M.E. 2nd, Talaat, A.M., 2017.
20 Superior protection from live-attenuated vaccines directed against Johne's disease.
21 Clin. Vaccine Immunol. 24, e00478-16,

1 Shook, G.E., Chaffer, M., Wu, X.L., Ezra, E., 2012. Genetic parameters for
2 paratuberculosis infection and effect of infection on production traits in Israeli
3 Holsteins. Anim. Genet. 43 Suppl 1, 56-64.

4 Singh, K., Chandel, B.S., Chauhan, H.C., Dadawala, A., Singh, S.V., Singh, P.K., 2013.
5 Efficacy of 'indigenous vaccine' using native 'Indian bison type' genotype of
6 *Mycobacterium avium* subspecies *paratuberculosis* for the control of clinical
7 Johne's disease in an organized goat herd. Vet. Res. Commun. 37, 109-114.

8 Skovgaard, K., Grell, S.N., Heegaard, P.M., Jungersen, G., Pudrith, C.B., Coussens,
9 P.M., 2006. Differential expression of genes encoding CD30L and P-selectin in
10 cattle with Johne's disease: progress toward a diagnostic gene expression
11 signature. Vet. Immunol. Immunopathol. 112, 210-224.

12 Slana, I., Pribylova, R., Kralova, A., Pavlik, I., 2011. Persistence of *Mycobacterium*
13 *avium* subsp. *paratuberculosis* at a farm-scale biogas plant supplied with manure
14 from paratuberculosis-affected dairy cattle. Appl. Environ. Microbiol. 77, 3115-
15 3119.

16 Sohal, J.S., Singh, S.V., Singh, A.V., Singh, P.K., 2010. Strain diversity within
17 *Mycobacterium avium* subspecies *paratuberculosis*--a review. Indian J. Exp. Biol.
18 48, 7-16.

19 Sohal, J.S., Arsenault, J., Labrecque, O., Fairbrother, J.-H., Roy, J.-P., Fecteau, G.,
20 L'Homme, Y., 2014. Genetic structure of *Mycobacterium avium* subsp.
21 *paratuberculosis* population in cattle herds in Quebec as revealed by using a
22 combination of multilocus genomic analyses. J. Clin. Microbiol. 52, 2764–2775.

1 Sorge, U., Kelton, D., Lissemore, K., Godkin, A., Hendrick, S., Wells, S., 2010. Attitudes
2 of Canadian dairy farmers toward a voluntary Johne's disease control program. J.
3 Dairy Sci. 93, 1491-1499.

4 Sorge, U.S., Lissemore, K., Godkin, A., Hendrick, S., Wells, S., Kelton, D., 2011.
5 Associations between paratuberculosis milk ELISA result, milk production, and
6 breed in Canadian dairy cows. J. Dairy Sci. 94, 754-761.

7 Stabel, J.R., 2000. Transitions in immune responses to *Mycobacterium paratuberculosis*.
8 Vet. Microbiol. 77, 465-473.

9 Stabel, J.R., Goff, J.P., 2004. Efficacy of immunologic assays for the detection of Johne's
10 disease in dairy cows fed additional energy during the periparturient period. J. Vet.
11 Diagn. Invest. 16, 412-420.

12 Stabel, J.R., 2006. Host responses to *Mycobacterium avium* subsp. *paratuberculosis*: a
13 complex arsenal. Anim. Health Res. Rev. 7, 61-70.

14 Stabel, J.R., Robbe-Austerman, S., 2011. Early immune markers associated with
15 *Mycobacterium avium* subsp. *paratuberculosis* infection in a neonatal calf model.
16 Clin. Vaccine Immunol. 18, 393-405.

17 Stabel, J.R., Barnhill, A., Bannantine, J.P., Chang, Y.F., Osman, M.A., 2012. Evaluation
18 of protection in a mouse model after vaccination with *Mycobacterium avium* subsp.
19 *paratuberculosis* protein cocktails. Vaccine 31, 127-134.

20 Stevenson, K., Alvarez, J., Bakker, D., Biet, F., de Juan, L., Denham, S., Dimareli, Z.,
21 Dohmann, K., Gerlach, G.F., Heron, I., Kopečna, M., May, L., Pavlik, I., Sharp,
22 J.M., Thibault, V.C., Willemsen, P., Zadoks, R.N., Greig, A., 2009. Occurrence of
23 *Mycobacterium avium* subspecies *paratuberculosis* across host species and

1 European countries with evidence for transmission between wildlife and domestic
2 ruminants. BMC Microbiol. 9, 212.

3 Storset, A.K., Hasvold, H.J., Valheim, M., Brun-Hansen, H., Berntsen, G., Whist, S.K.,
4 Djønne, B., Press, C.M., Holstad, G., Larsen, H.J., 2001. Subclinical
5 paratuberculosis in goats following experimental infection. An immunological
6 and microbiological study. Vet. Immunol. Immunopathol. 80:271-287.

7 Stratilo, C.W., Lewis, C.T., Bryden, L., Mulvey, M.R., Bader, D., 2006. Single-
8 nucleotide repeat analysis for subtyping *Bacillus anthracis* isolates. J. Clin.
9 Microbiol. 44, 777–782.

10 Streeter, R.N., Hoffsis, G.F., Bech-Nielsen, S., Shulaw, W.P., Rings, D.M., 1995.
11 Isolation of *Mycobacterium paratuberculosis* from colostrum and milk of
12 subclinically infected cows. Am. J. Vet. Res. 56,1322-1324.

13 Sweeney, R.W., 1996. Transmission of paratuberculosis. Vet. Clin. North Am. Food Anim.
14 Pract. 12, 305-312.

15 Sweeney, R.W., Whitlock, R.H., Rosenberger, A.E., 1992. *Mycobacterium*
16 *paratuberculosis* cultured from milk and supramammary lymph nodes of infected
17 asymptomatic cows. J. Clin. Microbiol. 30, 166-171.

18 Thakur, A., Aagaard, C., Stockmarr, A., Andersen, P., Jungersen, G., 2013. Cell-
19 mediated and humoral immune responses after immunization of calves with a
20 recombinant multiantigenic *Mycobacterium avium* subsp. *paratuberculosis*
21 subunit vaccine at different ages. Clin. Vaccine Immunol. 20, 551-558.

22 Thibault, V.C., Grayon, M., Boschioli, M.L., Hubbans, C., Overduin, P., Stevenson, K.,
23 Gutierrez, M.C., Supply, P., Biet, F., 2007. New variable-number tandem-repeat

1 markers for typing *Mycobacterium avium* subsp. *paratuberculosis* and *M. avium*
2 strains: comparison with IS900 and IS1245 restriction fragment length
3 polymorphism typing. J. Clin. Microbiol. 45, 2404–2410.

4 Thibault, V.C., Grayon, M., Boschioli, M.L., Willery, E., Allix-Béguet, C., Stevenson,
5 K., Biet, F., Supply, P., 2008. Combined multilocus short-sequence-repeat and
6 mycobacterial interspersed repetitive unit-variable-number tandem-repeat typing
7 of *Mycobacterium avium* subsp. *paratuberculosis* isolates. J. Clin. Microbiol. 46,
8 4091–4094.

9 Thirunavukkarasu, S., Plain, K.M., de Silva, K., Begg, D., Whittington, R.J., Purdie,
10 A.C., 2014. Expression of genes associated with cholesterol and lipid metabolism
11 identified as a novel pathway in the early pathogenesis of *Mycobacterium avium*
12 subspecies *paratuberculosis*-infection in cattle. Vet. Immunol.
13 Immunopathol. 160, 147-157.

14 Thompson, B.R., Clark, R.G., Mackintosh, C.G., 2007. Intra-uterine transmission of
15 *Mycobacterium avium* subsp *paratuberculosis* in subclinically affected red deer
16 (*Cervus elaphus*). NZ Vet. J. 55, 308-313.

17 Tiwari, A., VanLeeuwen, J.A., McKenna, S.L.B., Keefe, G.P., Barkema, H.W., 2006.
18 Johne's disease in Canada Part I: clinical symptoms, pathophysiology, diagnosis,
19 and prevalence in dairy herds. Can. Vet. J. 47, 874-882.

20 Tiwari, A., VanLeeuwen, J.A., Dohoo, I.R., Keefe, G.P., Weersink, A., 2008. Estimate of
21 the direct production losses in Canadian dairy herds with subclinical
22 *Mycobacterium avium* subspecies *paratuberculosis* infection. Can. Vet. J. 49,
23 569-576.

1 Trefz, P., Koehler, H., Klepik, K., Moebius, P., Reinhold, P., Schubert, J.K., Miekisch,
2 W. 2013. Volatile emissions from *Mycobacterium avium* subsp. *paratuberculosis*
3 mirror bacterial growth and enable distinction of different strains. PLoS ONE 8,
4 e76868.

5 Trier, L., Nielsen, S.S., Krogh. K., 2012. Motivation of farmers to reduce between-herd
6 transmission of paratuberculosis through repeated on-farm meetings with
7 discussion on certification. Page 318 in 11th Proc. International Colloquium on
8 Paratuberculosis Sydney, Australia.

9 Van Campen, H., Rhyen, J., 2010. The role of wildlife in diseases of cattle. Vet. Clin.
10 North Am. Food Anim. Pract. 26, 147–161.

11 van Hulzen, K.J., Nielen, M., Koets, A.P., de Jong, G., van Arendonk, J.A., Heuven,
12 H.C., 2011. Effect of herd prevalence on heritability estimates of antibody
13 response to *Mycobacterium avium* subspecies *paratuberculosis*. J. Dairy Sci. 94,
14 992-997.

15 van Hulzen, K.J., Koets, A.P., Nielen, M., Heuven, H.C., van Arendonk, J.A.,
16 Klinkenberg, D., 2014. The effect of genetic selection for Johne's disease
17 resistance in dairy cattle: Results of a genetic-epidemiological model. J. Dairy
18 Sci. 97, 1762-1773.

19 Van Kooten, H.C., Mackintosh, C.G., Koets, A.P., 2006. Intra-uterine transmission of
20 paratuberculosis (Johne's disease) in farmed red deer. NZ Vet. J. 54, 16-20.

21 Van Roermund, H.J.W., Bakker, D., Willemsen, P.T.J., de Jong, M.C.M., 2007.
22 Horizontal transmission of *Mycobacterium avium* subsp. *paratuberculosis* in
23 cattle in an experimental setting: Calves can transmit the infection to other calves.

1 Vet. Microbiol. 122, 270-279.

2 Van Schaik, G., Pradenas, F.M., Mella, N.A., Kruze, V.J., 2007. Diagnostic validity and
3 costs of pooled fecal samples and individual blood or fecal samples to determine
4 the cow- and herd-status for *Mycobacterium avium* subsp. *paratuberculosis*. Prev.
5 Vet. Med. 82, 159-165.

6 Van Weering, H., van Schaik, G., van der Meulen, A., Waal, M., Franken, P., van
7 Maanen, K., 2007. Diagnostic performance of the Pourquier ELISA for detection of
8 antibodies against *Mycobacterium avium* subspecies *paratuberculosis* in individual
9 milk and bulk milk samples of dairy herds. Vet. Microbiol. 125, 49-58.

10 Velthuis, A.G.J., Weber, M.F., de Koeijer, A.A., Van Roermund, H.J.W., 2006. A milk
11 quality assurance program for Johne's disease: decision analysis from a farmer's
12 perspective. Proc. 11th Symp. Intern. Soc. Vet. Epidemiol. Econ., Cairns, Australia,
13 p. 313.

14 Verdugo, C., Pleydell, E., Price-Carter, M., Prattley, D., Collins, D., de Lisle, G., Vogue,
15 H., Wilson, P., Heuer, C., 2014a. Molecular epidemiology of *Mycobacterium*
16 *avium* subsp. *paratuberculosis* isolated from sheep, cattle and deer on New
17 Zealand pastoral farms. Prev. Vet. Med. 117, 436-446.

18 Verdugo, C., Jones, G., Johnson, W., Wilson, P., Stringer, L., Heuer, C., 2014b.
19 Estimation of flock/herd-level true *Mycobacterium avium* subspecies
20 *paratuberculosis* prevalence on sheep, beef cattle and deer farms in New Zealand
21 using a novel Bayesian model. Prev. Vet. Med. 117, 447-455.

1 Waddell, L.A., Rajic, A., Stärk, K.D.C., McEwen, S.A., 2015. The zoonotic potential of
2 *Mycobacterium avium* ssp. *paratuberculosis*: A systematic review and meta-
3 analyses of the evidence. *Epidemiol. Infect.* 143, 3135-3157.

4 Waddell, L.A., Rajic, A., Stärk, K.D.C., McEwen, S.A., 2016. The potential public health
5 impact of *Mycobacterium avium* ssp. *paratuberculosis*: global opinion survey of
6 topic specialists. *Zoonoses Public Health* 63, 212-222.

7 Wang, J., Pritchard, J.R., Kreitmann, L., Montpetit, A., Behr, M.A., 2014. Disruption of
8 *Mycobacterium avium* subsp. *paratuberculosis*-specific genes impairs *in vivo*
9 fitness. *BMC Genomics* 15, 415.

10 Weber, M.F., van Schaik, G., 2007. Results of the Dutch milk quality assurance
11 programme for paratuberculosis. In: *Proc. 8th Intern. Colloq. Paratuberculosis*, pp.
12 325-327.

13 Weber, M.F., Groenendaal, H., van Roermund, H.J., Nielen, M., 2004. Simulation of
14 alternatives for the Dutch Johne's disease certification-and-monitoring program.
15 *Prev. Vet. Med.* 62, 1-17.

16 Weber, M.F., van Roermund, H.J., Vernooij, J.C., Kalis, C.H., Stegeman, J.A., 2006a.
17 Cattle transfers between herds under paratuberculosis surveillance in The
18 Netherlands are not random. *Prev. Vet. Med.* 76, 222-236.

19 Weber, M.F., Kogut, J., de Bree, J., van Schaik, G., 2006b. Survival analysis of age at
20 onset of shedding of *Mycobacterium avium* ssp. *paratuberculosis*. In: *Proc. 11th*
21 *Symp Int Soc Vet Epidemiol Econ*, Cairns, Australia, p. 444.

22 Wells, S.J., Wagner, B.A., 2000. Herd-level risk factors for infection with
23 *Mycobacterium paratuberculosis* in US dairies and association between

1 familiarity of the herd manager with the disease or prior diagnosis of the disease
2 in that herd and use of preventive measures. J. Am. Vet. Med. Assoc. 216, 1450-
3 1457.

4 Wells, S.J., Hartmann, W.L., Anderson, P.L., 2008. Evaluation of progress made by dairy
5 and beef herds enrolled in the Minnesota Johne's Disease Control Program. J. Am.
6 Vet. Med. Assoc. 233, 1920-1926.

7 Wentink, G.H., Bongers, J.H., Zeeuwen, A.A., Jaartsveld, F.H., 1994. Incidence of
8 paratuberculosis after vaccination against *M. paratuberculosis* in two infected
9 dairy herds. Zentralbl. Veterinarmed. B 41, 517-522.

10 Whist, A.C., Liland, K.H., Jonsson, M.E., Sæbø, S., Sviland, S., Østerås, O., Norström,
11 M., Hopp, P., 2014. Designing a risk-based surveillance program for
12 *Mycobacterium avium* ssp. *paratuberculosis* in Norwegian dairy herds using
13 multivariate statistical process control analysis. J. Dairy Sci. 97, 6835-6849.

14 Whipple, D., Kapke, P., Vary, C., 1990. Identification of restriction fragment length
15 polymorphisms in DNA from *Mycobacterium paratuberculosis*. J. Clin.
16 Microbiol. 28, 2561-2564.

17 Whitlock, R.H., Buergelt, C., 1996. Preclinical and clinical manifestations of
18 paratuberculosis (including pathology). Vet. Clin. North Am. Food Anim. Pract.
19 12, 345-356.

20 Whitlock, R.H., Wells, S.J., Sweeney, R.W., Van Tiem, J., 2000. ELISA and fecal culture
21 for paratuberculosis (Johne's disease): sensitivity and specificity of each method.
22 Vet. Microbiol. 77, 387-398.

23 Whittington, R.J., Hope, A.F., Marshall, D.J., Taragel, C.A., Marsh, I., 2000. Molecular

1 epidemiology of *Mycobacterium avium* subsp. *paratuberculosis*: IS900 restriction
2 fragment length polymorphism and IS1311 polymorphism analyses of isolates from
3 animals and a human in Australia. J. Clin. Microbiol. 38, 3240-3248.

4 Whittington, R., Marsh, I., Choy, E., Cousins, D., 1998. Polymorphisms in IS1311, an
5 insertion sequence common to *Mycobacterium avium* and *M. avium* subsp.
6 *paratuberculosis*, can be used to distinguish between and within these species. Mol.
7 Cell. Probes 12, 349-358.

8 Whittington, R.J., Windsor, P.A., 2009. *In utero* infection of cattle with *Mycobacterium*
9 *avium* subsp. *paratuberculosis*: a critical review and meta-analysis. Vet. J. 179, 60-
10 69.

11 Whittington, R.J., Fell, S., Walker, D., McAllister, S., Marsh, I., Sergeant, E. Taragel, C.A.,
12 Marshall, D.J., Links, I.J., 2000a. Use of pooled fecal culture for sensitive and
13 economic detection of *Mycobacterium avium* subsp *paratuberculosis* infection in
14 flocks of sheep. J. Clin. Microbiol. 38, 2550-2556.

15 Whittington, R.J., Reddacliff, L.A., Marsh, I., McAllister, S., Saunders, V., 2000b.
16 Temporal patterns and quantification of excretion of *Mycobacterium avium* subsp
17 *paratuberculosis* in sheep with Johne's disease. Aust. Vet. J. 78, 34-37.

18 Whittington, R.J., Marsh, I.B., Whitlock, R.H., 2001. Typing of IS 1311 polymorphisms
19 confirms that bison (*Bison bison*) with paratuberculosis in Montana are infected
20 with a strain of *Mycobacterium avium* subsp. *paratuberculosis* distinct from that
21 occurring in cattle and other domesticated livestock. Mol. Cell Probes 15, 139-145.

22 Whittington, R.J., Marsh, I.B., Taylor, P.J., Marshall, D.J., Taragel, C., Reddacliff, L.A.,
23 2003. Isolation of *Mycobacterium avium* subsp. *paratuberculosis* from

1 environmental samples collected from farms before and after destocking sheep with
2 paratuberculosis. Aust. Vet. J. 81, 559-563.

3 Whittington, R.J., Marshall, D.J., Nicholls, P.J., Marsh, I.B., Reddacliff, L.A., 2004.
4 Survival and dormancy of *Mycobacterium avium* subsp. *paratuberculosis* in the
5 environment. Appl. Environ. Microbiol. 70, 2989-3004.

6 Whittington, R.J., Marsh, I.B., Saunders, V., Grant, I.R., Juste, R., Sevilla, I.A., Manning,
7 E.J., Whitlock, R.H., 2011. Culture phenotypes of genomically and geographically
8 diverse *Mycobacterium avium* subsp. *paratuberculosis* isolates from different
9 hosts. J. Clin. Microbiol. 49, 1822-1830.

10 Windsor, P.A., Whittington, R.J., 2010. Evidence for age susceptibility of cattle to Johne's
11 disease. Vet. J. 184, 37-44.

12 Windsor, P.A., Eppleston, J., Dhand, N.K., Whittington, R.J., 2014. Effectiveness of
13 Gudair vaccine for the control of ovine Johne's disease in flocks vaccinating for at
14 least 5 years. Aust. Vet. J. 92, 263-268.

15 Wolf, R., Barkema, H.W., De Buck, J., Slomp, M., Flaig, J., Hauptstein, D., Pickel, C.,
16 Orsel, K., 2014. High herd-level prevalence of *Mycobacterium avium* subspecies
17 *paratuberculosis* in Western Canadian dairy farms, based on environmental
18 sampling. J. Dairy Sci. 97, 6250-6259.

19 Wolf, R., Barkema, H.W., De Buck, J., Orsel, K., 2015a. Sampling location, herd size
20 and season influence *Mycobacterium avium* ssp. *paratuberculosis* environmental
21 culture results. J. Dairy Sci. 98, 275-287.

1 Wolf, R., Orsel, K., De Buck, J., Barkema, H.W., 2015b. Calves shedding
2 *Mycobacterium avium* subspecies *paratuberculosis* are common on infected dairy
3 farms. Vet. Res. 46, 71.

4 Wolf, R., Barkema, H.W., De Buck, J., Orsel, K. 2016. Dairy farms testing positive for
5 *Mycobacterium avium* ssp. *paratuberculosis* have poorer hygiene practices and
6 are less cautious when purchasing cattle than test-negative herds. J. Dairy Sci. 99,
7 4526-4536.

8 Wolf, R., Donat, K., Khol, J.L., Barkema, H.W., Kastelic, J., Wagner, P. 2017. Detection
9 of *Mycobacterium avium* subspecies *paratuberculosis* infected cattle herds using
10 environmental samples: a review. Berl. Munch. Tierarztl. Wochenschr. 130, 4-12.

11 Wraight, M.D., McNeil, J., Beggs, D.S., Greenall, R.K., Humphris, T.B., Irwin, R.J.,
12 Jagoe, S. P., Jemmeson, A., Morgan, W.F., Brightling, P., Anderson, G.A.,
13 Mansell, P.D., 2000. Compliance of Victorian dairy farmers with current calf
14 rearing recommendations for control of Johne's disease. Vet. Microbiol. 77, 429-
15 442.

16 You, Q., Verschoor, C.P., Pant, S.D., Macri, J., Kirby, G.M., Karrow, N.A., 2012.
17 Proteomic analysis of plasma from Holstein cows testing positive for
18 *Mycobacterium avium* subsp. *paratuberculosis* (MAP). Vet. Immunol.
19 Immunopathol. 148, 243-251.

20 Zhong, L., Taylor, D., Begg, D.J., Whittington, R.J., 2011. Biomarker discovery for ovine
21 paratuberculosis (Johne's disease) by proteomic serum profiling. Comp. Immunol.
22 Microbiol. Infect. Dis. 34, 315–326.

- 1 **Table 1.** Most important knowledge gaps that hamper prevention and control of *Mycobacterium avium* subspecies *paratuberculosis*
- 2 (MAP) infection

Area	Knowledge gap
Control programs	<ul style="list-style-type: none"> - (Long-term) efficacy of control programs - Is eradication of MAP infection in a herd possible?
Prevalence	<ul style="list-style-type: none"> - Comparison of MAP prevalence over time in the same region - Comparison of prevalence in different regions using the same test (regime)
The pathogen	<ul style="list-style-type: none"> - Distribution of MAP genotypes - Differences in virulence, pathogenicity, immunogenicity, persistence, transmission, survival outside the host, and host specificity between genotypes - Effect of mixed genotype infections and superinfections
Tests	<ul style="list-style-type: none"> - Characteristics of tests in a population that reflects the target population - Development of reliable early stage diagnostics - Reliable on-farm tests - Value of detection of immunoglobulin isotypes other than IgG - Most accurate and cost-effective set of environmental samples and sampling interval (dairy) - Best DNA extraction protocols for PCR analyses - How to quantify MAP in tissues, blood, milk, and feces - Validation of biomarkers in naturally infected cattle
Transmission	<ul style="list-style-type: none"> - Role of MAP shedding young stock - Relative importance of various transmission routes (including transmission through dust and drinking water) - Influences on survival of MAP in soil and on pasture) - Minimal infectious dose for animals of all ages - Consequence and importance of intra-uterine transmission - Shedding pattern of MAP-infected animals, including role of supershedders - Effectiveness of commercial pasteurizers at reducing viable MAP bacteria in colostrum
Role of wildlife	<ul style="list-style-type: none"> - Validation of diagnostic tests for wildlife - Prevalence of MAP in wildlife - Impact of MAP infections on wildlife health

Susceptibility	<ul style="list-style-type: none"> - Magnitude of the role wildlife plays as MAP reservoir and in transmitting MAP to farmed animals - Economic benefits of reducing MAP transmission from wildlife to livestock - Influences on susceptibility and the progression of MAP infection (e.g., age, genetics,...) - Genetic heritability of MAP infection - Difference in susceptibility among breeds - Identification of genetic markers associated with MAP susceptibility, disease progression, and response to vaccination - Benefit of the IFN-γ assay in genetic linkage studies - Interaction between host genotype and MAP genotype
Vaccination	<ul style="list-style-type: none"> - Development of a cattle vaccine that limits infection and/or shedding, and does not interfere with diagnostics for other mycobacterial infections - Better understanding of immune evasion and immune modulation strategies of MAP - Characterization of diversity of MAP strains to select the most appropriate vaccine strain - Definition of protective immune response by vaccination - Appropriate level of attenuation of vaccine strains to elicit immune response without causing disease - Differentiation between infected and vaccinated animals
Uptake	<ul style="list-style-type: none"> - Influences on farmers' motivation to enroll in (voluntary) disease prevention and control programs and implement recommended management strategies - How to overcome the "wait-and-see" mindset - Veterinary practitioners' role in promoting control program participation including communication - Potential of approaches that address Johne's disease in combination with other fecal-orally transmitted diseases